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Introduction – Treatment for breast cancer is associated with a risk of chronic shoulder and upper 
limb morbidity in up to 30% of patients. There is currently no consensus for the possible reason for 
this often repeated finding in the literature. Previous research has suggested that development of 
fibrotic tissue in response to cancer treatments such as surgery and radiotherapy could be an 
underlying cause of musculoskeletal dysfunction and pain. This study investigated if any genetic 
variants in several key fibrosis-modulating genes could be shown to be associated with risk of upper 
limb musculoskeletal dysfunction and pain in breast cancer survivors. 
 
Participants and Methods – A cross sectional study design was employed, using a candidate gene 
approach. A total of 326 South African breast cancer survivors were recruited from a tertiary hospital 
in the Western Cape (343 total, minus 17 samples with insufficient data collected). Each participant 
was scored for symptom severity using the shoulder pain and disability index (SPADI) questionnaire. 
Participants were then grouped for symptom severity using low, med or high SPADI scores. The low 
SPADI group served as controls (controls n=273, cases n=70). Participants were invited to donate 
a blood sample from which DNA was extracted. Each DNA sample was genotyped at seven 
polymorphic sites; three in TGF-ß, two in ATM, one in SOD2 and one in XRCC1, using PCR 
technologies and TaqMan allelic-discrimination probes. The resultant genotypes were analysed 
using multivariate analysis, including inferred haplotype analysis to search for association to 
shoulder pain and morbidity after treatment. A logistic regression analysis was also performed to 
investigate the association between SPADI score and age of participant. 
 
Results – When participant age was compared with symptom severity, it was found that younger 
participants were more likely to have moderate-to-severe symptoms than older participants. There 
was a significant difference in the minor allele frequencies between case and control groups for the 
rs4880 (C>T, SOD2) polymorphism. The T allele was present more in the case group than in 
controls, with minor allele frequencies of 0.67 vs 0.55 respectively. No other independent 
associations were noted for any of the remainder variants tested. When haplotypes were inferred 
for genes SOD2 and ATM, combinations between the rare alleles at rs4880 and rs1800058 (C>T, 
ATM) were associated (F=4.35, p<0.01) with a low SPADI score. 
 
Conclusions – Based on these results, the allele combination between SOD2 rs4880 C>T and 
ATM rs1800058 is recommended for further study, in addition to the rs4880 polymorphism in SOD2. 
These novel results are suggesting that there may be an association between fibrotic genes and the 
development of upper limb sequelae after treatment for breast cancer. A larger case-control study 
would be required to validate and explore these findings. 
 





Introduction and Scope of Dissertation 
 
This project was intended to explore a facet of a central research area from a larger 
study (HREC 2012-312).  
 
It has been observed that some women, after treatment for breast cancer, suffer from 
long lasting and debilitating symptoms, affecting the upper limbs and shoulder joints. 
This area of research is largely underexplored, especially in a South African context 1. 
Due to this paucity in research, healthcare professionals have limited resources to 
diagnose and treat this morbidity. Consequently, patients are not offered satisfactory 
information nor treatment, which adversely affects their quality of life. For these 
reasons, it was decided to investigate the self-reported symptoms experienced by 
patients after treatment for breast cancer. The aim of the research was to explore a 
link between genetic sequence variation and prevalence of symptoms, to better inform 
further research and potential treatment options. 
 
The aim of this research was to test the hypothesis that an association could be found 
between variation in a gene (or multiple) and the SPADI score (as a measure of tissue 
damage). This was achieved by the following objectives: genotyping the participants 
at several key SNP loci and statistically analysing the results against their SPADI 
scores to identify any associations; comparing participant age against SPADI score to 
determine any association between age and SPADI score. 
 
Chapter 1 reviews the current literature body of previously conducted research into 
the topic of late morbidity in tissue after treatment for breast cancer, using the 
published research from Shamley et al. (2007, 2014) as a basis 1–3. The citations within 
these papers were then investigated, used to develop a bibliography, and used  to 
compile the list of search terms. At the conclusion of the literature review, a list of 





Table 1.1.1 – A list of the genes selected for inclusion within the study, and the specific genetic 
polymorphism under investigation. Samples were genotyped at the; rs1800469 c.1347 C>T TGF-ß, 
rs1800472 c.788 C>TGF-ß , rs4880 c.47 C>T SOD2, rs25487 c.1196 A>G XRCC1, rs1800058 c.4258 
C>T ATM and rs1801516 c.5557 G>A ATM polymorphisms in Mixed Ancestry South African population. 
Gene SNP 
TGF-ß  rs1800469  
TGF-ß  rs1800471  
TGF-ß  rs1800472 




Abbreviations: SNP, single nucleotide polymorphism. 
 
The literature review, Chapter 1, starts with an overview of breast cancer and its 
epidemiology within the targeted population of female South African, breast cancer 
survivors. The various treatment modalities for breast cancer were then presented 
including known complications. This section sought to find links in the literature 
between the treatment of breast cancer and musculoskeletal disease. The next 
section investigated fibrosis in general, and then presented evidence linking fibrosis 
to the pathology observed after breast cancer treatment. Finally, a list of candidate 
single nucleotide polymorphisms (SNPs) presented, which was compiled using 
previous literature and clinical research into key genes linked to fibrosis. 
 
Chapter 2 - presents the materials and methods of the genetic association study 
conducted investigating links between genetic sequence variation and the clinically 
observed outcomes. In Chapter 3 - the results are provided, along with statistical 
analyses used to achieve the research goals. Finally, Chapter 4 - discusses the novel 
findings of this paper, and the possible biological implications of these findings. It 
discusses the potential clinical implications and potential future treatment modalities 
for fibrosis. In addition, future research directions are presented including the areas of 









1.1  Literature search 
The databases PubMed, Scopus, Medline and the Cochrane Foundation were first 
searched for published work. The date of publication range was set from the years of 
1986 - 2018 (unless otherwise noted). This ensured that research collated is based 
on modern research, with minimal exclusion of informative material. 
 
The literature search commenced using a hand search of records provided at the 
outset of the project from the research team. This began with papers published by 
Shamley et al. A list of chosen keywords was then developed to conduct the following 
database search: (“breast cancer” OR “breast neoplasm” OR “breast carcinoma”) AND 
(“surgery” OR “chemotherapy” or “radiotherapy” OR “treatment”) AND (“fibrosis” OR 
“fibrotic” OR “scarring” OR “shoulder dysfunction” OR “shoulder pain”). The second 
main search conducted used the same keywords, with the exclusion of breast cancer 
specific terms (“cancer” rather than “breast cancer” etc), and the results were collated. 
This was done in order to collect relevant articles concerning similar morbidity in other 
cancers, not included in the breast cancer specific literature search. Records selected 
from this search process were first reviewed by title, if they matched the search criteria, 
the abstract, followed by full body, was reviewed. This process resulted in 78 records, 
with the study, outlined in Figure 1.1.1. Further articles were accessed using citations 
from this literature body. Finally, gene/SNP specific keywords (“Gene name” OR 
“accession number”) and outcome keywords were searched for, in order to locate any 
potential unexplored related pathologies. Results from all of these searches were 





Figure 1.1.1 - Flow chart describing the initial literature review, the steps taken to screen and identify 
records used for inclusion, with the number of records included at each step, and the breakdown of the 




1.2  Breast cancer in South Africa 
Globally, breast cancer is one of the most common forms of cancer, it is also one of 
the most treatable forms, having the highest survival rates for long term prognosis of 
any cancer 4. This success is partly due to the ability to remove breast tissue without 
catastrophic consequences for the individual 5–7. Despite these factors, this form of 
cancer contributed to 12.7% of cancer mortality worldwide in 2008, with a 16.6% share 
of all cancer diagnoses in women 4,7–9. Breast cancer is, like in many countries, the 
most common form of cancer in South Africa, with 14,097 new cases of breast cancer 
in estimated 2018. This is an incidence rate of 24.55 (new diagnoses per 100,000 
people per year), which comprises 13.1% of all South African cancer diagnoses 10,11. 
However, South Africans have a lower reported incidence of breast cancer cases than 
most western countries; for example, the same source estimates the incidence rate 
for the United Kingdom at 83.27 in 2018 12. This could be due to a number of biological 
factors such as a later menarche and a relatively early maternal age at birth of the first 
child, both factors that are associated with decreased breast cancer risk due to the 
later onset of hormonal cycle/fluctuation 13–15. Lower reported incidence rates could 
also be due to socio-economic factors and standards of healthcare within South Africa. 
These factors can include poor access to diagnostic facilities among isolated 
rural/impoverished areas, poor education, poor awareness of early cancer self-
detection practices, and inadequate reporting standards for prevalence and morbidity 
of breast cancer 7,16. 
 
In the subsequent years since the end of apartheid, the South African national 
healthcare system has transformed into an integrative, comprehensive national 
service 17. Many factors have hindered this transformation however, including 
economic disparity, poor national leadership and the HIV crisis. South Africans remain 
an underserved population, South Africa is technically considered a middle-income 
country, whilst health outcomes underperform many lower income countries. This is 
to be expected to be a contributing factor to the underperformance in cancer diagnosis 
and treatment. For example, a study conducted in the Western Cape reported an 
average time to diagnosis (of breast cancer) of eight and a half months after first self-
identification of physical symptoms, which was primarily attributed to lack of education 




Another example is the disparity in healthcare spending; less than 15% of the 






1.3  Treatment of breast cancer 
At the stage of diagnosis, an individual's breast cancer is rated according to stage of 
progression. In the early stages, breast cancer is confined to a single tumour colony, 
either in breast tissue, or the surrounding lymphoid tissue. When identified early as a 
single tumour, surgical removal of the tumour can be enough to halt the disease 
entirely, with or without the requirement for adjuvant therapy. However, once able to 
colonise other remote tissues and metastasize, the cancer is now malignant, which 
increases complexity of treatment and worsens prognosis 5. Survival rates are much 
lower in cases where diagnosis is made later. Breast cancer is not female-specific, but 
it is much rarer in males, who make up less than 1% of cases, and differ in cancer 
biology 6,12,19.  
 
Surgery physically removes solid tumours, while chemotherapy (CT), hormone 
therapy (HT) and radiotherapy (RT) aim to impede tumour cell reproduction through 
various biological signalling pathways and/or chemical damage 5. These treatments 
are explored in more detail below. 20 
 
1.3.1  Surgery 
The earliest recorded surgery for breast cancer was by cauterising drill in ~3000BC. 
More recently, the Romans excised the entire breast and/or pectoralis muscle in 
~100BC. Unfortunately for patients, little progress was made for nearly two millennia 
21. The next significant improvement was the recording of the breast anatomy, 
specifically vascular and lymphatic structures in the 1500’s. The first recognisable 
surgical procedure was the Halsted Radical Mastectomy, published by William Halsted 
in 1894 21. Although undeniably a disfiguring operation, a remarkable 40% of patients 
survived to five years post-surgery, a significant accomplishment for the time 21. The 
current standard in surgery, the modified radical mastectomy (MRM), was published 
in 1972 by John Madden, which preserves both pectoral muscles 20,22. 
 
Surgical techniques have since progressed, which has led to development of 
procedures where healthy breast tissue as well as underlying muscle and connective 




are treated with a radical or MRM and/or traditional external beam radiotherapy. This 
is partly due to late diagnoses, when a mastectomy is the only pragmatic option. This 
surgical practice may lead to complications in the tissues of the upper limbs 25. 
 
1.3.2  Radiotherapy 
RT is the standard treatment protocol in cases where local surgery is considered 
inadequate to reliably remove cancerous tissue and is predominantly delivered via an 
external beam 6,25,26. This external beam uses ionising photon radiation to selectively 
destroy the reproductive ability of cells, by acting directly on DNA and depositing 
energy into the molecular structure, and indirectly by forming reactive oxygen species 
5. If delivered in small doses, the cellular DNA repair machinery is able to repair the 
damaged DNA with acceptable speed and accuracy. However with enough damage 
through larger doses of RT, the repair function stalls at the G2/M checkpoint with the 
biological purpose of stalling the reproduction of damaged cells into daughter cells 
with similar damage. These cells which are unable to undergo mitosis ultimately die 
by either apoptosis or necrosis. Cancerous cells that undergo mitosis regardless of 
this DNA damage (due to non-function of the stalling mechanism) usually do so in a 
haphazard and incomplete way which results in apoptosis or necrosis within a few 
divisions 27,28.  
 
1.3.3  Radiotherapy morbidity  
The high-energy beams used to deliver radiotherapy cannot discriminate between 
healthy and pathological tissue. As a result, it is inevitable that healthy tissue local to 
the target area will also be irradiated, and that side effects of this irradiation will 
sometimes present after treatment, either in the irradiated tissue, or in areas directly 
adjacent to the irradiated zone in this local stroma. This is in contrast to 
pharmacological therapies, where side effects are typically systemic, affecting all parts 
of the body to which the drug molecules are distributed by the circulatory systems.  
 
As a result of this radiation damage, healing pathways are initiated which include a 
number of inflammatory and repair cytokines, the effects of which can be far ranging 




the completion of the course. Typical symptoms can include erythema of the skin, 
mucositis, nausea and diarrhoea. Late effects are more often present in the range of 
months to years after treatment and include radiation-induced fibrosis (RIF), atrophy 
of tissue, vascular degeneration, neural damage and deregulation of endocrine 
system function 31,32. Progress in molecular radiobiology over recent years has vastly 
improved the understanding of the mechanisms of radiation pathogenesis, which is 
vital considering the increased population of cancer survivors who have undergone 
radiotherapy 33,34. 
 
1.3.4  Radiation-induced pulmonary fibrosis 
One of the first documented examples of pathology as a result of radiotherapy is that 
of radiation pneumonitis (RP). RP is the acute clinical manifestation of radiation-
induced pulmonary fibrosis (RIPF). The later manifestation of this is severe radiation 
fibrosis of the lungs 35,36. RIPF was first observed in patients undergoing RT and 
surgery for lung cancer in 1922, while the risk of developing RP was first quantified in 
a large cohort study by Lingos et al. (1990) 37. Research performed into RIPF and 
similar conditions provided potential insights into possible causes of the clinical signs 
exhibited within the population of this study 38.  
 
As stated, RIF was initially investigated in lung tissue, and has also been studied in 
other organ systems after cancer treatment. These include prostate cancer, bowel 
cancer, liver etc.29,34,39,40. A lot of useful data can be gleaned from these studies, but 
few studies involve musculoskeletal tissue, such as in the shoulder complex. As such 
there may be very different pathological factors in play. 
 
In the final stage of late manifestation, RIPF is a serious disease, characterised by 
excessive deposition of extracellular matrix (ECM), which reduces lung function and 
leads to difficulty breathing 41,42. In addition to this, the ECM destroys function of 
alveolar-capillary membranes, leading to hypoxemia and hypertension. This can be 
fatal without lung transplant. During investigation into the pathophysiology, there 
appear to be competent anti-fibrotic mechanisms in the soma, which may be 
malfunctioning 42. An individual’s response to the ionising effects of RT and other 




component as well as environmental factors such as diet, smoking status and age 43–
45. 
 
The prevailing view for much of the previous century was that dosage received by a 
cell/tissue was the predominant factor for the increased risk of developing RIPF. The 
theory states that tissue is damaged by cellular death from receiving RT, which leads 
to functional deficiency of that tissue 46. However, increasingly the shift in paradigm is 
to a model by which radiation instigates a biochemical reaction in tissue mediated by 
signalling molecules, resulting in ECM deposition and mesenchymal cell proliferation 
which characterise fibrosis in connective tissue 47. Attempts have been made to 
develop a predictive assay for individual response to RT, but as of yet no universal 
clinically applicable assay has been developed 47.  
 
1.3.5  Direct beam and intraoperative radiotherapy 
In response to this increased knowledge of radiotherapy-induced pathology, forms of 
treatment that aim to minimise this risk have been developed. Modern treatment 
facilities use radio-emitting devices that modulate the shape and orientation of the 
beam in three dimensions. This allows practitioners to deliver precise quantities of 
radiation and minimise erroneous irradiation 48. This is performed under the hypothesis 
that the total dose of radiation received by healthy tissue is dosimetrically proportional 
to the damage done to the tissue, which is likely to be an oversimplification 49. 
 
Within the field of radiation therapy, it quickly became necessary to strike a healthy 
balance between the therapeutic dose of any radiation received and the associated 
toxicity that RT exhibits towards healthy tissue. The study of this interaction has 
become a greater area of study as the burden of cancer survivorship post-radiotherapy 
has grown, initially in more economically developed countries and increasingly in the 
rest of the world with the dissemination of medical technology. 
 
1.3.6  Radiogenomics 
Andreassen et al. formed the term radiogenomics to broadly encompass the response 




pharmacogenomics, radiogenomics broadly deals with the response to radiotherapy 
by the genetic component of the cell – “radiobiology meets molecular pathology” in a 
paper by Andreassen et al. (2002, p.1) 47. Specifically, it refers to the role of genetic 
variation in response to exposure to radiation received as part of medical treatment. 
This information, along with improvements in radiobiology, allow greater advances in 
treating and preventing RT induced morbidity. Research into radiogenomics has 
initially focused on candidate SNP sites, but whole genome technologies are 
increasingly becoming more feasible for research 43,51. 
 
The study of certain genetic diseases, such as ataxia telangiectasia, Fanconi’s 
anaemia and Mijmegen breakage syndrome 51–54, has provided evidence that tissue 
radio-sensitivity can be determined by genetic factors. All of these conditions derive 
from genetic abnormality in the cellular DNA damage repair systems. Patients 
suffering from these conditions have been shown to be more clinically radiosensitive 
than the general population 53. This is also supported by animal studies, in which 
mammals such as the scid mouse have mutations in similar DNA damage/repair 
genes and suffer from extreme radiosensitivity 54,55. 
 
1.3.7  Chemotherapy 
As RT refers to treatment in the form of radiation, CT refers to the use of chemical 
agents to treat cancer 56. Chemotherapy is the use of non-specific intracellular 
poisons, rather than molecules that have specific categories of targets, such as in 
hormonal therapy that target receptors. 
 
One of the most commonly used chemotherapeutic agents is cisplatin, a metallic 
compound of platinum complexed with water, ammonia and chloride ions 57,58. 
Cisplatin and other drugs with similar mechanisms of action are in the class of 
‘cytotoxic’ drugs, and form an essential component in the treatment of malignant 
breast cancer 57,59. When introduced to cellular conditions the chlorine ion is displaced 
by water to form cis-[PtCl(NH3)2(H2O)]. This complex is then able to bind to DNA 
bases, which stalls cellular mitosis, and initiates DNA repair mechanisms. This 




destroys cancerous cells due to the ability of cisplatin to preferentially kill cells which 
replicate quickly. 
 
Although a highly effective treatment, cisplatin treatment is associated with a range of 
side effects. The most severe of these being a risk of developing nephrotoxicity, due 
to the cisplatin being cleared by the kidneys and accumulating within the kidney tissue 
58,60. This occurs via membrane-bound copper transporters which are highly 
expressed in kidney cells. Once within the kidney tissue, cisplatin is metabolically 
processed into more toxic forms, which damage both nuclear and mitochondrial DNA, 
leading to cell death 58–60 and nephrotoxicity.  
 
Chemotherapy-induced peripheral neuropathy (CIPN) is a common complication for 
cancer survivors who have been treated with certain CT agents (cisplatin, thalidomide, 
taxol) 29,61. CIPN is caused by the direct anti-mitotic and anti-angiogenic action of the 
drugs 61,62. This loss of vascular tissue and other forms of toxic damage leads to axonal 
degradation, causing a loss of sensation and pain alongside other associated 
symptoms. The risk of these symptoms developing is a major limiting factor in 
chemotherapy. Once the neuropathies present symptomatically they are generally 
lifelong and incurable. As the population of cancer survivors grows, so does the burden 
of CT related disease 61,63. 
 
As the burden of CIPN, and other cancer treatment-caused diseases has risen, so has 
the research conducted into potential treatments. One example of this is vascular 
endothelial growth factor (VEGF) gene therapy, which has been shown to inhibit the 
endothelial vascular tissue damage associated with CT, although no accepted form of 
treatment exists for use in human treatment 62. 
 
1.3.8  Hormonal and targeted therapy 
Hormonal therapies are anti-cancer agents that specifically target pathways of growth 
management. This is achieved through affecting chemical signallers of growth and 





The role of growth hormones in breast tissue growth and differentiation has been 
known since the end of the 19th century. The primary hormonal regulators of growth 
are progesterone and oestrogen, which are both produced in the ovaries 64.There are 
two major oestrogen receptors; oestrogen receptor alpha (ERα) and beta (ERβ). Once 
the growth hormone molecules have been transported into the nucleus of the cell, the 
molecules bind to and activate these oestrogen and progesterone receptors. This 
effects cellular growth by altering levels of transcription. The alpha oestrogen receptor 
is expressed in 70% of cancer cases increasing the rate of cellular growth 64. ERα 
ablation as a form of adjuvant therapies were investigated, leading to the discovery of 
tamoxifen by Harper & Wolpole in 1967 64. Tamoxifen is one of the most frequently 
used hormonal therapies for breast cancer treatment, belonging to the class of 
selective oestrogen-receptor modulating drugs 64–66. 
 
Another form of HT is aromatase inhibitor (AI) drugs, which inhibit the aromatase 
catalysed synthesis of oestrogen 64. One side effect of this type of HT drug is that it 
reduces levels of oestrogen amongst post-menopausal women. A study found, that 
amongst 437 Chinese women undergoing AI therapy, 11% had to prematurely 
discontinue AI therapy. The primary cause of discontinuation was joint pain amongst 
57% of these women 67. Another study reported that 10% of patients required a change 
of AI after development of severe sequela, of which joint pain (arthralgia) was the most 
commonly reported side effect68. 
 
As with many other treatments, HT is also associated with side effects. One of the 
most significant sequelae is arthralgia. One study reported that after two years post-
treatment, 71% of women still reported arthralgia 69. This joint pain has been shown 
to have significant impact on quality of life. 
 
1.3.9  Therapy related cancers 
Many of the treatment modalities for cancer create an associated increased risk of 
developing secondary cancers, termed therapy-related cancers. These secondary 
cancers can be due to the ionising radiation of radiotherapy destabilising the genomes 
of otherwise healthy tissue. Another cause could be from cytotoxic therapies 




related cancers are unusual in that they have specific and quantifiable aetiological 
factors. The study of these cancers has led to several advances in understanding the 
role of the loss of DNA repair pathways in leading to genomic instability, including DNA 
double strand break gene translocation 56. 
 
Finally, RT and CT can interact with other pre-existing factors, such as diet, cigarette 
smoking and genetic predisposition to cancer 56. As shown, the treatment of cancer is 
often associated with treatment sequelae. In breast cancer, these side effects often 
manifest in the upper torso, shoulder and upper limb regions. The risk of these therapy 
related cancers, along with the risk of RT/CT sequelae, are two of the major dose 





1.4  Shoulder joint complex and treatment  
While drug therapies exert their effect systemically, surgery and RT exert a local effect 
initially. In breast cancer these local tissues primarily comprise the upper limb and 
shoulder. The tissue immediately surrounding the breast tissue are musculoskeletal 
and connective tissue components of the shoulder. The shoulder joint complex is the 
most mobile joint in the body and healthy movement of the joint requires unhindered 
movement of the gleno-humeral joint and the scapula over the surface of the thorax 3. 
These motions, when combined, are known as scapula-humeral rhythm and are 
required when lifting and mobilising the arm. Further movement is achieved by 
coordination of the muscles acting across the joints 3. There are a number of points 
during movement where pathology can affect this motion. Loss of function or stiffness 
in one muscle or muscle group will also affect the action of the antagonist muscle 
groups shown in Error! Reference source not found. leading to possible 
compensation injuries and dyskinesia in the opposing musculature. An example of this 
is shoulder impingement syndrome, where inflammation of the sub-acromial tendon 
can lead to impingement of the tendon against the acromion process, causing pain 
when lifting the limb laterally. 
 
 
Figure 1.4.1 – Posterior (left) and anterior (right) view of the shoulder joint, with labelling of several key 
anatomical structures for shoulder stability and movement. Reproduced from Gray’s Anatomy (1918) 







1.4.1  Clinical evidence 
The previous section discussed the complexity of the shoulder joint, and the effects 
that musculoskeletal dysfunction will exert on this fragile joint. This section will explore 
the clinical evidence in the literature showing the disease burden on the population 
and the justification for conducting research into possible causative factors for a 
shoulder joint injury in breast cancer patients.  
 
Many women who are successfully treated for breast cancer, later complain of a range 
of symptoms that cause pain and affect the function of the shoulder joint and upper 
arm. These symptoms have been noticed immediately and up to six years post-
surgery 3. This limits the ability of women to return to normal lifestyle after convalescing 
3. Upon investigation, Shamley et al. (2014) reported that 10-55% of women in a 
European cohort of breast cancer survivors showed restricted range of motion (ROM), 
22-38% reported shoulder pain, and 42-56% of patients reported difficulty with lifting 











Figure 1.4.2 – A method of assessing range of motion of the shoulder. A patient is asked to move their 
aim from resting to vertical (1-4), and the limit of comfortable motion is used as an assessment. Adapted 
from Caban et al. (2006) 71. 
 
The most comprehensive meta-analysis into this shoulder and upper limb 
phenomenon found was conducted by Rietman et al. (2003) into late morbidity of the 
arm after surgery 72. Studies were assessed on patient population, study design, 
confounding factors and correct documentation of cohort. Studies were also assessed 
overall for reliability and validity. Within this meta-analysis six studies were found to fit 
their inclusion criteria. The main reason for exclusion was inconsistency between 
reports including lack of standardised shoulder assessment. Within the European 
cohort studies analysed, the prevalence of reported pain 12 months post-surgery 
ranged from 12-51%, which increased to 23-39% in the follow up between 14 to 38 
months 72. The prevalence of restricted range of motion of the treated side arm varied 
from 2-51%, with radical mastectomy showing most significant loss of ROM (Figure 
1.4.2). Prevalence of edema was 6-43%, suggesting issues related to incorrect 




relationship between breast cancer treatment and late upper limb mobility, Rietman et 
al. (2003) stressed that the strength of the relationship was low, and more work was 
needed 72. A more recent meta-analysis indicated that the vast majority of studies 
showed evidence of shoulder impairment as a late effect from breast cancer 
treatments, with effects varying from small to substantial 73. A similar conclusion was 
reached by Hidding et al. (2014) 74. Some reviews indicated a stronger correlation 
between variants and late effect severity in patients who received adjuvant RT, as 
compared to patients treated only surgically 75. Similar results have been reported by 
other groups such as Tengrup et al. (2000), Johansen et al. (2014) and Karki et al. 
(2004) 76–78. 
 
After treatment for breast cancer kinematic changes to scapula-humeral rhythm and 
altered muscular control were observed 1,3. In a study of 155 women treated for 
unilateral breast carcinoma, patients demonstrated a different movement dysfunction 
depending on whether the right or the left shoulder had been affected 1,3. Muscle 
dysfunction was observed in both the cancer affected and unaffected side of patients, 
with use of adjuvant treatment 1,3. These patterns of movement observed were similar 
to that seen in known shoulder conditions such as frozen shoulder syndrome/adhesive 
capsulitis, suggesting possible underlying trends that link the aetiology of several 
shoulder conditions with similar characteristics 1,3. Shamley et al. (2014) used 
electromyography within a sample of 74 women (post breast cancer treatment) and 
results indicated that there was a decrease in muscular activity in several of the key 
muscles acting on the shoulder complex during upper arm movement 1. This decrease 
in muscular activity was seen the upper trapezius, pectoralis major, pectoralis minor, 
serratus anterior and rhomboid muscles. The pectoralis muscles lie within the field of 
surgery and radiotherapy for breast cancer treatment, this damage can therefore be 
expected. However neither of the trapezius or rhomboid muscles fall within the field of 
surgery or RT for breast cancer, which indicates ‘secondary effects’ from surgery or 
RT. These effects have been shown to persist up to five years after breast cancer 
treatment 1,3.  
 
A recent review serves to show that modern advances in surgical technique and RT 




(2015) studied 159 women following their outcome after breast cancer surgery & three 
dimensional conformal radiotherapy over a period of seven years. At a follow-up three 
months’ post-surgery, participants were asked to rate their pain or discomfort in their 
arms or shoulders; 37.6% reported slight to severe pain in the arm or shoulder. This 
indicates that even with advanced and more modern conformal RT techniques, 
symptoms are still widely present 30. However, at three months post-surgery, the time-
frame is still too recent to indicate a chronic condition, as the local/systemic response 
to surgical trauma and adjuvant treatment may not have resolved.  
 
Caban et al. (2006) after following up arm or shoulder pain 12 months post-surgery, 
suggested that the full impact of radiation induced sequelae might take longer to 
present, and suggested a five year follow up period to adequately show late effects 71. 
Supporting this, Bentzen at al. (2001) found that 90% of radiotherapy damage was 
present within 3.7-4.2 years post-surgery, depending on clinical covariates 31. 
 
1.4.2  Axillary web syndrome 
One form of specific pathology observed in this upper limb morbidity is axillary web 
syndrome (AWS). AWS manifests as a visible web of axillary skin overlying palpable 
cords of tissue which become taut during shoulder abduction. This extends from the 
axilla towards the thumb which makes it painful to touch and creating tightness and a 
pulling sensation on the surrounding tissue as reported by Moskovitz et al. (2001). 
AWS has also been shown to affect ROM of the shoulder joint, which may be due to 
the cords causing the shoulder to be taut during abduction 79.  
 
Despite small sample sizes, differences in classification and testing modalities, AWS 
prevalence after breast cancer surgery has been reported at 6-72% 2,79–82. Kohler et 
al. (2013) noted that more aggressive forms of surgery, including removal of all 
connective tissue, adipose tissue and lymph nodes seem to predispose AWS 
development 81. Upon investigation, immunohistological findings in the literature 
suggest the cord may be comprised of fibrosed and stased vessels, of either lymphatic 
or vascular origin 82,83. A fibrosed cord could adhere to the surrounding fascial plane 





1.4.3  Frozen shoulder 
The focus of this literature review is to explore outcomes after specific anti-cancer 
treatments. Other non-cancer reported conditions affecting the shoulder joint share 
similar symptoms, often with idiopathic onset, which could include underlying similar 
pathological mechanisms. An example of this is frozen shoulder syndrome (FS), a 
disease loosely defined in both aetiology and pathophysiology (also frequently 
referred to as frozen shoulder or adhesive capsulitis). First identified as a distinct 
condition in 1934 85, frozen shoulder shares similar characteristics to the shoulder pain 
and disability described in this paper. Acquired FS is due to a causative factor such 
as surgery or trauma, whilst FS is idiopathic if there is an absence of any known 
causative factor. Bentzen et al. (2001) studied the loss of ROM after radical 
mastectomy and RT, and compared it to FS 31. One study found that the average age 
for developing FS was ~50 years old, this observation correlates with a common age 
for breast cancer, although no causation is implied by this observation 86. A 
monozygotic twins study by Hakim et al. (2003) showed that the risk of developing FS 
is strongly heritable 87. This suggests a strong genetic link to FS, and possibly genetic 
links to similar pathologies. 
 
In attempting to treat FS, Hand et al. (2007) took arthroscopic biopsies of rotator 
interval tissue and subjected them to histological and immunocytochemical analysis. 
This revealed the presence of excess, proliferating fibroblasts and an infiltrate of 
inflammatory cells, which are hallmarks of chronic fibrosis 88. This pathogenic 
progression of inflammation to fibrosis is frequently referenced in other papers 88–93. It 
is possible that FS and shoulder pain and disability (SPAD or SPADI) share similar 
pathologies. 
 
1.4.4  Connective tissue and fascia 
More advanced medical procedures are endeavouring to preserve as much tissue as 
possible during the mastectomy. This is considered with the intention of minimising 
the risk of post-treatment secondary disease. The fascia, is a series of connective 
tissue sheaths covering the musculoskeletal system, which are comprised mainly of 




(i.e tendons) and also contains adipocytes and other non-connective tissue aspects 
94. 
 
Removal of the pectoralis fascia is considered an essential part of a standard radical 
mastectomy, for the purpose of minimising the risk of any residual cancerous tissue 
remaining. However, this assertion is not supported by all evidence. Several studies 
have shown that there is no significant risk of remittance when fascia-sparing 
procedures are used 83. A retrospective study on 1031 patients who underwent a 
MRM, but not RT was performed by Katz et al. (2001) 95. It was found that patients 
with pectoralis major fascia (PF) invasion had a 33% risk of relapse in ten years 
compared to 18% risk of relapse without PF invasion (p=<0.001). However, this was 
only found in univariate analysis, and the difference was not observed in multivariate 
analysis. This lead to the conclusion that the relapses could have been due to PF 
invasion or to increased invasiveness of more aggressive tumours. Senelein et al. 
(2004) performed 235 MRM’s without removal of the PF, and local relapse rate was 
6.4% at five years post-surgery, this led to the conclusion that the procedure is 
oncologically safe 96. It is yet unclear as to whether the removal of the fascia is 
necessary or not. An increasing body of research indicates that connective tissue such 
as pectoralis major fascia has more bio-kinetic importance than previously imagined 
94,96,97, which consequently impacts the function of the shoulder after treatment. 
 
1.4.5  Fibrosis 
As discussed, RT is highly damaging to living tissue and is capable of causing genetic 
damage which leads to cellular destruction long after the initial treatment morbidity has 
abated. Many links have been made between RT (for breast cancer), SPAD and 
fibrotic tissue found within the tissue 43,98. Tissue toxicity has shown a range of 
asymptomatic changes in tissue structure and function. Early reactions occur within 
90 days of treatments, with late effects presenting after 90 days 33. Early reactions 
affect tissues that have a high metabolic turnover, such as the skin, gastrointestinal 
tract and bone marrow, due to the rapid rate at which healthy, pre-damage cells are 
replaced with post-radiation, damaged cells 99. In contrast to this, tissues which 
turnover at a lower rate generally present later, such as tendons, muscles and bone 




not directly radiated. This is via a proposed pathway whereby cells damaged by 
ionising radiation release cytokine signalling molecules that can diffuse through tissue, 
or be transmitted through cell to cell gap junctions, which cause a pro-reaction in cells 
not immediately irradiated 100–102. It is believed that this cell damage can result in 
fibrotic plaques within soft tissue after RT 103. Fibrotic plaques, comprising of inert 
connective tissue will not serve the contractile function required of muscle tissue. This 
will alter function and place additional compensatory stress on surrounding tissue, 
exacerbating issues and potentially having huge effects on quality of life. 
 
One of the most comprehensive sources of evidence linking fibrosis to cancer 
treatment is a meta-analysis conducted by Westbury et al. (2012) 98. This meta-
analysis consisted of a comprehensive literature review into the topic of morbidity and 
side effects after treatment for cancer (RT/CT/HT), and was the broadest meta-
analysis found in terms of size and duration. In addition to this, Shamley et al. (2007) 
reported gross areas of connective tissue in the shoulders of women upon autopsy 
after radiotherapy. As described in Figure 1.4.3, fibrotic areas of connective tissue can 
be observed in the affected shoulder of a patient at autopsy. The area of intense blue 
response to a connective tissue stain can be seen in contrast to the more moderate 
connective tissue stain response on the unaffected shoulder of the patient, in which 









Figure 1.4.3 – Histological changes between unaffected side (left), and affected side (right) of upper 
limb at autopsy, showing pathological changes in structure to tissue. Patient treated with radiotherapy. 
Azure blue stain was used to indicate presence of connective tissue in blue. A – unstained adipose 
tissue. F – collagen fibres. D – blood vessels. Reproduced with permission from Shamley et al. 
(personal communication). 
 
A description frequently used in the literature for the progression of fibrotic tissue is ‘a 
wound that doesn’t heal’ 103,104. This reflects the evidence that the molecular 
mechanism of radiation fibrosis appears to share mechanisms involved in normal 
wound healing, as described in Figure 1.4.3. In healthy healing, the process involves 
distinct phases as described in Figure 1.4.4 36. The significance is that in the final 
stage of healthy healing, active cells involved in the healing response (myofibroblasts, 
inflammatory cells, reactive oxygen species defence, immune cells) either undergo 
apoptosis, migrate away or mature and decrease in activity. This feature is typically 
missing in chronic, progressive fibrosis 34,54,105–107. Research suggests that genetic 
variation in genes coordinating these wound healing biological pathways could impact 
the degree to which individuals are susceptible to this pathology 47,53,54. This genetic 
association, if shown to be present, could indicate that post breast cancer treatment, 
it would be possible to identify individuals at a high risk for fibrotic progression. This 
could allow preventative or management treatment plans to be developed to mitigate 





Figure 1.4.4 – The proposed model for development of fibrosis following cancer treatment. Genetic variation controls the actions of the cellular healing pathways following 
cellular insult, either promoting healthy healing and a return to normal tissue function, or degradation into a dysfunctional state of chronic disease, due to proposed but unproven 




1.4.6  Shared pathogenic pathways in cancer and fibrosis  
The pathophysiology of both cancer and fibrosis are associated with regions of hyper-
proliferative stromal cells, particularly myofibroblasts 104,108. Myofibroblasts are 
fibroblasts that have undergone endothelial-mesenchymal-transition (EMT), and are 
associated with areas of mass deposition of extracellular matrix components as well 
as instigating fibrotic processes through paracrine effects on surrounding stromal 
cells. The ECM deposited in this form of chronic fibrosis has an altered composition, 
comprising of higher levels of collagens I and III compared to normal collagen 
composition. Myofibroblasts also act physically, by contracting on the surrounding 
ECM 104,105. Some authors have suggested that cancerous tissue in a region can 
predispose the region to fibrosis, and vice-versa 105,109. Other forms of potential 
interplay between cancer and fibrosis exist, for example in the processes of 
inflammation. The inflammation present surrounding a tumour site (for example in 
breast cancer) has inflammatory factors which can additionally drive EMT and 




1.5  Biomolecular pathways in fibrosis  
Development of fibrotic tissue within the shoulder complex following either RT, CT or 
HT has been hypothesised to be a major cause of the shoulder pain and dysfunction 
suffered post treatment. The inter-person variability of symptom severity is high. It is 
possible that some of this inter-patient variation is due to differing levels of activity in 
key fibrotic pathways. This has been shown to be the case in similar pathologies in 
different tissues. The most frequently reported pathways are those involved in DNA 
damage repair, inflammatory response and oxidative stress 44. 
 
1.5.1  Reactive oxygen species 
Several pathways are involved in mitigating the intra-cellular damage caused by 
reactive oxygen species (ROS), which are formed by the high-energy radiotherapy 
beam. ROS is a molecule capable of oxidising cellular components, including proteins, 
DNA and lipids 44,45. These molecules are regarded as a form of intracellular signalling 
53 and are naturally generated as part of normal cellular reduction/oxidation reactions 
and there are pathways within the cell that mitigate and repair the damage, for 
example via the action of anti-oxidant peptides such as glutathione and thioredoxin 
44,45. In this capacity they are believed to activate cellular stress pathways 107,111. ROS 
generation forms an aspect of the cytotoxic effectiveness of RT. The massive oxidative 
damage destroys the structure of cells, by disrupting cellular macromolecules and 
through dysregulating cellular processes 45. This complements the direct ionising 
effect of RT, as such it is believed that genetic variation within genes coding for ROS 
defence proteins is believed to alter an individual’s reaction to ROS damage 43,44,112,113. 
 
1.5.2  Genetic variation 
Research presented in the previous sections has shown that inflammatory and 
damage repair pathways are heavily involved with the response to cancer treatment. 
Differences however in population, disease and treatment modality provide 
confounding factors that can complicate the process of identifying viable gene targets 
114,115. In addition, studies often do not reliably produce positive results and often 
produce results with low confidence 99,116–119. It is a general consensus within the 




no single master genetic ‘switch’ towards fibrosis has been identified 43. Due to this 
lack of knowledge, the following sections will explore genetic variation as a potential 




1.6  Candidate gene approach 
In order to investigate links between SPADI symptoms and genetic variation a 
candidate gene genetic association study was performed. The aim of genetic 
association studies is to identify an association between one or more genetic variants 
and a trait 120,121. Genetic association studies can be used in a case-control design, 
for example, a group of individuals with a severe tissue response to RT can be 
compared to a group of individuals who did not have this abnormal response to RT. 
Statistical analysis can then determine whether a candidate genetic variant or group 
of variants are over-represented in one of these groups compared to the other. If this 
is found to be the case, then one, or a group of variations can be said to be associated 
with this outcome. This association is not proof that a variant is responsible for an 
outcome, but it can provide putative targets for future investigation. The candidate 
gene approach is used when candidate genetic variants are identified prior to 
experimentation for having a potential biological role in the studies end-point and is a 
hypothesis driven approach. Candidate variants are usually identified by reviewing the 
literature into similar outcomes, normally disease states or phenotypes, and are 
similarly limited by the degree of limitation of the knowledge of underpinning biology 
120,121. 
 
Polymorphisms within a gene can affect the polypeptide product in different ways. 
Either by variation in the amount of protein produced, or change in the structure and 
function of the protein. This change in protein structure and function can have 
amplified net effects in downstream biological pathways. In this way even a minor 
change in a protein coding sequences can have a significant result on the final 
biological outcome.  
 
1.6.1  Transforming growth factor-beta 
Transforming growth factor beta (TGF-ß) (19q13.2) is a widely expressed critical gene 
family with a large variety of roles. These roles are primarily related to modulating 
cellular differentiation, growth, proliferation and apoptosis 103,122,123. In relation to 




differentiation during tumour progression. Due to this, it is frequently studied in relation 
to cancer biology, chronic fibrosis, musculoskeletal diseases and more 44. 
 
TGF-ß is a hugely influential factor in modulating cellular events. TGF-ß activity 
regulates the proliferation and differentiation of cells, wound healing, and 
angiogenesis and receptors for it are found in almost all tissues 124,125. Figure 1.6.1 
shows the activation of inactive TGF-ß dimers into active TGF-ß, recognition by the 
TGF-ß(1,2,3) receptors, and transduction of the intracellular signal, primarily through 
via mothers against decapentaplegic homolog (SMAD) complexes, which translocate 
to the nucleus and act as transcription factors 106. 
 
 
Figure 1.6.1 – A functional model showing inactive TGF-ß complexes, recognition by the receptor, and 
internal SMAD complexes that facilitate gene transcription, along with integration into other signal 
transduction pathways. Adapted from Pohlers et al. (2009) with permission 34. Key abbreviations; TGF-
ß, transforming growth factor beta; SMAD, mothers against decapentaplegic homolog. 
 
 
Using the model of TGF-ß activity presented in Figure 1.6.1, an increased amount of 
TGF-ß1 protein produced will increase the amount of molecule/receptor binding. This 




transduction of signalling pathways increasing ECM deposition and decreasing 
degradation of ECM. 
 
TGF-ß activity has been linked to many fibrotic conditions, including atherosclerosis 
and fibrotic disease of the kidney, liver, and lung. In one study, breast cancer patients 
with significantly higher than normal TGF-ß serum concentrations were 90% more 
likely to suffer from idiopathic interstitial fibrosis after chemotherapy for breast cancer 
126. Another observational study of 91 women showed that higher levels of TGF-ß 
levels pre-RT was prognostic for the severity of the response to RT 127. TGF-ß protein 
levels are included on lists of ‘frailty’ biomarkers, referring to risk of loss of muscle tone 
and coordination associated with aging 128–131. 
 
One of the key manifestations of TGF-β activity in wound healing is activation of 
quiescent fibroblasts into myofibroblasts, which have a high capacity for ECM 
synthesis and form plaques of connective tissue. This fibrotic tissue is not capable of 
performing the biological function of the muscle and connective tissue that it is 
replacing and will affect the function of the musculoskeletal system as a whole. 
Activation of TGF-ß and the subsequent myofibroblast differentiation has been shown 
to be triggered by the physical flow of interstitial fluid into an area 70,132. Additionally, it 
has been accepted that irradiation of somatic cells induced increased activity of TGF-
ß and other pro-fibrotic genes 133–135. However, results are not universally 
corroborated, and often correlation based rather than causally linked and the exact 
mechanism is not confirmed 27,135–137. TGF-ß has also been studied in relation to 
fibrosis in conditions such as pulmonary fibrosis and gastrointestinal fibrosis 
conditions 38,138–142.  
 
Skin and connective tissue have been shown to have increases in TGF-ß gene activity 
in a biphasic manner after injury, with twin peaks of increased activity after irradiation 
indicating activation of latent TGF-ß protein and de novo synthesis apparent two-four 
weeks after injury 34. This is exacerbated by an associated increase in the TGF-ßR2 
receptor productions due to positive feedback mechanisms 34. It has also been shown 
that levels of TGF-ß can be a reliable indicator for risk of fibrosis after radiotherapy for 




studies have shown that inhibition of SMAD knockdown can inhibit the progression of 
fibrosis and relieve the restricted range of motion in murine models 92. 
 
Figure 1.6.2 shows a summary of this fibrosis process and the believed influence of 
TGF-ß activity. Once fully progressed, fibrosis is extremely slow to self-correct, if not 
permanent. One potential prophylactic treatment could be attempting to intervene and 
modulate the early stages of fibrosis, which could be feasible if at-risk patients could 
be identified early enough in the process.  
 
 
Figure 1.6.2 – A cellular model for the production and activation of TGF-ß after tissue injury; with the 
function of the TGF-ß protein either leading to normal healing and self-shutdown (3a) or a failure to -
self-shutdown leading to a disease state (3b). Abbreviations; ECM, extra cellular matrix; TGF-ß, 





Intra-gene variance in TGF-ß has been shown to be influential in driving individuals’ 
pre-disposition to fibrosis 43,143,144. Rs1800469 C>T is the most frequently reported site 
within the literature and has a clear proven increase on amount of TGF-ß protein 
produced 124. Minor alleles at this particular polymorphism site can lead to increased 
amount of TGF-ß activity in cells, with reports by Shah et al. (2006) of up to twice as 
much protein in serum 124. Rs1800469 is located within the promotor region of TGF-
ß, and the T allele variant at this polymorphism prevents binding of a regulatory 
protein, thereby increasing the amount of TGF-ß produced. TGF-ß gene activity also 
drives a positive feedback loop that drives additional TGF-ß production, amplifying the 
effect of the variant allele 125,136. In another study by Grainger et al. (1999), T 
homozygous individuals at rs1800469 produced up to twice as much TGF-ß1 
compared to the C homozygous individuals 146.  
 
Three candidate polymorphism sites within TGF-ß were selected, rs1800469 C>T, 
rs1800471 C>G and rs1800472 G>A. These were all considered to have sufficient 
evidence to be viable candidates for inclusion in this study. Rs1800470 G>A was 
initially also considered, but was discounted for further investigation as it was found in 
high LD with rs1800469 and thus the presence of one indicates the presence of the 
other 147. 
 
1.6.2  Interleukin-6 
The interleukin-6 (IL-6) (7p15.3) cytokine, along with other members of the IL family, 
is an important mediator in the acute phase of injury response. IL-6 has a pro-
inflammatory role, and also serves as a growth factor for fibroblasts. In mouse models, 
IL-6 null mice showed a delayed wound healing response due to diminished 
myofibroblast differentiation 99. Myofibroblasts are crucial to fibrosis, by releasing 
signalling factors that maintain an inflammatory response to injury. In addition to this, 
myofibroblasts in some tissues have been shown to produce IL-6 protein, providing a 
feedback mechanism which could drive fibrosis 106,148,149. In observational studies of 
patients after RT, serum levels of IL-6 rise, which is not true for other interleukin family 
members, and this has been linked to an increased risk of radiation pneumonitis in 





1.6.3  X-ray repair cross-complementing protein 1 
Another studied protein is X-ray repair cross-complementing protein 1 (XRCC1) 
(19q13.31), one of the core proteins involved in base excision repair 151. It is believed 
to be a scaffold structure which coordinates the correct sequence of repair by other 
members of the base excision repair pathway 152. XRCC1 has also been investigated 
for its role in fibrosis. In a study of telangiectasia, fibrosis and atrophy in breast cancer 
patients, XRCC1 variant genotypes were found to be positively correlated with 
increasing symptom severity (along with TGF-ß) 99. This is consistent with results 
found by other groups 152–155. Polymorphisms present in other members of the X-ray 
repair cross-complementing protein (XRCC) protein family have been linked to 
morbidity after treatment, but XRCC1 has been most consistently linked and is 
believed to be the most promising gene for investigation 156,157. The strongest 
candidate SNP site was rs25487 T>C with numerous reports finding links between 
variation and late effects after RT and other forms of treatment 158. 
 
1.6.4  Superoxide dismutase 
Neutralising the harmful effects of intracellular ROS is a crucial aspect of the response 
to ionising damage. This is necessary to minimise oxidation damage which if 
unchecked, can rapidly lead to necrosis. The gene superoxide dismutase 2 (SOD2) 
(6q25.3) is crucial to this process. The protein SOD2 acts by binding to superoxide, 
the by-product of oxidative phosphorylation, using manganese ions to catalyse the 
conversion into hydrogen peroxide (H202) and diatomic oxygen (02). This maintenance 
of internal ROS levels is crucial and highly conserved. In this way, SOD2 activity is 
highly cytoprotective, and has links to promoting tumour growth in cancer. Evidence 
in the literature links a polymorphic variant in the SOD2 gene (rs4880 A>G) tissue 
response to RT. This variant is believed to affect the structure of the protein, and alter 
the ability of the protein to migrate into the mitochondria 36,47,159. This variant (rs4880) 
leads to a reduction in the amount of protein produced and has been linked to 
increased survival in breast cancer patients treated with surgery and tamoxifen 113. It 
is known that part of the effectiveness of RT is indirectly through generation of ROS 




enhance the effectiveness of RT to induce ROS damage. It is not completely 
understood how changes in the levels of intracellular ROS affects the ability of pre-
cancerous tissue to progress into cancer. As such, it is not possible to predict 
accurately the effect of structural change or expression level of SOD2 on the risk of 
developing cancer at this time. 
 
Andreassen et al. (2003) reported that amongst mastectomy patients genotypic 
variation at the rs4880 polymorphism in SOD2 was associated with an increased risk 
of subcutaneous fibrosis leading to fibrotic disease 43. Tentative correlations of this 
variant to symptoms has been reported in other studies 63-72. rs4880 was considered 
a viable candidate for inclusion in this study 45,113,152,160. 
 
1.6.5  Tumour necrosis factor-alpha 
Inflammatory pathways are activated in response to threats such as pathogens, 
infection and injury and serve various functions. Tumour necrosis factor-alpha (TNFα) 
(6p21.33) signalling controls expression levels and influences TGF-ß signalling as part 
of inflammation 161–163.  
 
Polymorphisms within this gene have been linked to a disease phenotype. Helmig et 
al. (2011) studied individuals possessing homozygous wild type alleles for the 
rs1800629 G>A polymorphism which was shown to be linked to the highest TNFα  
messenger RNA (mRNA) expression. In contrast, the homozygous rare allele (A/A) 
showed the lowest mRNA expression 161. These results also correlated with lowered 
levels of TGF-ß mRNA expression 161. This could indicate that variants in TNFα can 
act as a pro or antifibrotic factor in an individual. This was supported in the measured 
values of 178 study participants in pulmonary idiopathic fibrosis 164.  
 
TNFα activity in fibrosis is indirect, and is as a result of its effect on TGF-ß activity. If 
TNFα polymorphisms were to be included in this study, it would mean that the end 
result (SPADI symptoms) are a result of an unknown (TNFα association) acting on 
another unknown (TGF-ß association). This indirect effect may well be beyond the 






1.6.6  Ataxia telangiectasia mutated 
The gene product of ataxia telangiectasia mutated (ATM) (11q22.3) is a 
Serine/Threonine kinase enzyme, which is activated following the detection of DNA 
double strand breaks in response to ionizing radiation. The ATM was first identified in 
studies of patients suffering from ataxia telangiectasia syndrome (AT) 157,165. In 
addition to the ataxia telangiectasia symptoms, it was also observed that these 
patients developed severe fibrosis after receiving RT 67,68. Because of the link to a 
known gene mutation, the ATM gene was one of the first to be investigated for an 
association with normal tissue radiosensitivity 44,157,165. However, individual reports of 
association is often unreproducible in other studies 157,159,165,166.  
 
A loss of function of the ATM protein would impede-cycle arrest after DNA repair, as 
is seen in ataxia–telangiectasia syndrome. In addition, non-functional ATM would be 
unable to phosphorylate and active p53, which is also an essential component cell-
cycle arrest 40,167,168. Finally, ATM and TGF-ß activity are linked via the SMAD 
transcription factors (two and seven), and it has been shown that functional TGF-ß 
signalling is required for ATM activation 169. This cross talk between ATM and TGF-ß 
has been shown to promote epithelial-mesenchymal transition and proliferation of 
fibroblasts in a renal model 167. The altered levels of ATM/p53 protein mediated 
cessation of cell cycle progression and associated growth could lead to cell death and 
atrophy in affected tissues. This uncontrolled cell necrosis and tissue atrophy could 
impede healing after cellular trauma and lead to tissue disruption/fibrosis and altered 
gross shoulder function 167,170. Two polymorphism sites, rs1800058 and rs1801516 
were included in the list of candidate sites for this study. 
 
An overview of the pathways featured in this section are presented in Figure 1.6.3. 
Several of the downstream genes within a given pathway have been shown, along 
with the action of each gene to either positively or negatively influence downstream 







Figure 1.6.3 – A diagram of interplay between several of the key cytokines and processes believed to influence the progression of fibrosis. Orange indicates a 
biological process, green is a gene name, red is an external stimulus. Dotted tips indicate that an interaction is negatively modulating expression, arrow tips 
indicate that the interaction is increasing overall expression. Abbreviations: SOD2, superoxide dismutase; XRCC1, x-ray repair cross-complementing protein; 
ATM, ataxia telangiastica mutated; TGF-ß, transforming growth factor beta; PDGF, platelet derived growth factor; TNFα, tumour necrosis factor alpha; SMAD, 





Table 1.6.1 – References for Figure 1.6.3. 
Reference Paper 
154 
Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen 
formation in vitro 
155 TGF-β: the master regulator of fibrosis 
156 
A portrait of Transforming Growth Factor superfamily signalling: Background 
matters. 
157 
TGF-β1 accelerates the DNA damage response in epithelial cells via SMAD 
signalling. 
158 
New tricks for an old fox: impact of TGFβ on the DNA damage response and 
genomic stability. 
159 TGF-β/SMAD Pathway and Its Regulation in Hepatic Fibrosis. 
160 
TGFβ1-Induced Activation of ATM and p53 Mediates Apoptosis in a SMAD 7-
Dependent Manner 
160 ATM And Related Protein Kinases: Safeguarding Genome Integrity 
161 A mechanism of suppression of TGF–b/SMAD signalling by NF-kB/RelA 
162 
MnSOD Overexpression Reduces Fibrosis and Pro-Apoptotic Signalling in the 
Aging Mouse Heart 
163 The structural basis of XRCC1-mediated DNA repair. 
164 
Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in 
epithelial–mesenchymal transition and chemoresistance in biliary tract cancer 
165 
Interleukin-6 regulation of transforming growth factor (TGF)-beta receptor 
compartmentalization and turnover enhances TGF-β1 signalling. 
105 Signalling in Fibrosis: TGF-β, WNT, and YAP/TAZ Converge 
166 TGF-β signalling in fibrosis. 
167 TGF-β signalling and the fibrotic response 
Abbreviations: SOD2, superoxide dismutase; XRCC1, x-ray repair cross-complementing protein; ATM, 
ataxia telangiastica mutated; TGF-ß, transforming growth factor beta; ROS, reactive oxygen species; 
BER, base excision repair.  





1.7  Summary 
To summarise, breast cancer is the most common cancer in the general female 
population but is one of the most effectively treated cancers 7. Treatment usually 
consists of surgical excision of the cancerous tissue, radiotherapy targeting any 
cancerous tissue believed to be left remaining, and depending on the characteristics 
of the cancers, forms of chemotherapy, or targeted therapies are used 73. Local 
therapies affect tissue in the shoulder complex, which is a highly mobile but fragile 
joint. Movement of blood, lymph and nerve signals from the trunk to the arm limb also 
traverse the shoulder joint and upper arm. 
 
Despite increasing success rates in treating breast cancer, a subset of patients are 
left with debilitating side effects, often affecting the shoulder and upper limb function. 
Previously published literature into similar symptoms have suggested that a 
pathological condition involved could be fibrosis, driven by the cellular insult of cancer 
treatment, leading to pain and discomfort within the shoulder joints. Further research 
leads to the possibility of a link between genetic variation at certain genes and an 
individual’s response to radiotherapy and other cancer treatments, either to return to 
healthy function or degenerate into dysfunctional healing. The size of effect of any 
polymorphisms is likely to be minor, and may be unnoticeable in the general 
population, only having a noticeable health affect in those who have undergone 
radiotherapy or other similar cancer therapies. 
 
The experimental design of a candidate gene association study has been explored, 
and candidate polymorphisms have been presented, with an overview of the research 
findings that justify their inclusion in this study. These polymorphisms alter the activity 
of genes within pathways that instigate and modulate fibrosis. Using this previously 
published literature, the list of candidate SNP sites was developed to include the 
genes; TGF-ß, SOD2, ATM and XRCC1. Table 1.7.1 describes the candidate gene 
variants. Genotyping a cohort of participants at these sites was performed to 
determine if an association could be found statistically to the mentioned disease. This 
could indicate these SNPs as targets for future research, as well as further validating 







Table 1.7.1 – Overview of the candidate genes and single nucleotide polymorphisms. 
Gene Function of Gene Product NCBI dbSNP id SNP 
Minor 
allele 
Minor allele freq 
(1000genome) 
Functional 
change Consequence of variant 
TGF-ß Pro-fibrotic cytokine 
rs1800469 





↑ in amount of protein 
produced 
(113,172,173,178–180) 
rs1800471 Promotor, c.74 G>C C 0.048 Arg > Pro 
↓ in amount of protein 
produced 
(113,172,173,181) 
rs1800472 c.788 C>T T 0.01 Thr > Ile 






rs1800058 c.4258 C>T T 0.01 Leu > Phe 
Altered function 
(174,173) 
rs1801516 c.5557 G>A A 0.07 Asp > Asn 
Altered function 
(40,140,182) 
XRCC1 DNA repair (BER) rs25487 c.1196 A>G G 0.26 Gln > Arg 
Altered function 
(140,145,176) 
SOD2 ROS scavenger rs4880  c.47 C>T C 0.41 Ala > Val 
Decrease in activity (†) 
(146,147,183) 
Abbreviations: SOD2, superoxide dismutase; XRCC1, x-ray repair cross-complementing protein; ATM, ataxia telangiastica mutated; TGF-ß, transforming 
growth factor beta; BER, base excision repair. 








2.1  Introduction  
Breast cancer is typically treated with a combination of surgery, chemotherapy, 
hormonal therapy and radiotherapy 72. While often successful in treating cancer, all of 
these therapies are associated with side effects, and a range of late sequelae that can 
last indefinitely 3. In breast cancer, one such treatment complication is a 
musculoskeletal dysfunction, in the form of upper limb morbidity and shoulder pain 
after treatment for breast cancer, which researchers have quantified into the shoulder 
pain and disability index (SPAD or SPADI) 1,3. This index uses a two part questionnaire 
to quantify the degree of the upper limb and shoulder morbidity as self-reported by the 
patient. 
 
In the literature review, much of the previous literature available studying this shoulder 
pain and disability was explored. One proposed aetiology was that the cytotoxic effects 
of cancer treatments have led to improper formation of fibrotic tissue within the 
shoulder, which is responsible for causing observed symptoms 2,36,123,171,172. Although 
the aetiology of this uncontrolled fibrosis is speculative, several genetic pathways are 
known to be crucial in modulating the fibrotic process . These include inflammatory 
pathways, DNA repair, oxidative repair, cell differentiation, cell cycle arrest and ECM 
management 99,115,139,153,173–176. Research into similar diseases has shown that several 
key sites of genetic variation within genes in these pathways can be crucial in 
modulating fibrosis. This is due to the functional variation altering the activity levels of 
the protein produced. Variations in TGF-ß, ATM, SOD2 and XRCC1 were investigated 
44,99,178–180,115,118,119,153,155,156,176,177. 
 
Each of these genes encode proteins that function enzymatically within pathways that 
potentially influence fibrosis. TGF-ß is a crucial and pluripotent signalling gene family, 
that encode proteins implicated in numerous cellular processes including cell 
differentiation, maturation, apoptosis and damage repair processes 173. Several 
reports have independently identified variants within TGF-ß as increasing the amount 






XRCC1 protein functions as a key scaffold protein in the repair of single-strand DNA 
breaks from ionising radiation during breast cancer treatment. Giotopoulos et al. 
(2007) showed an association between polymorphisms in XRCC1 and severity of late 
effects after RT, as have other researchers 99,115,119,155,183,184. 
 
The ATM protein is a serine/threonine kinase enzyme that activates DNA damage 
checkpoint in response to double stranded DNA breaks. This is achieved by ATM 
phosphorylating proteins that initiate a mediating response by halting cell cycle 
progression, and either commencing DNA repair or apoptosis 40,115,119,168,177,185. 
 
The final candidate gene, SOD2, codes for multiple protein isoforms depending on 
splicing. SOD2 protein works to convert cytotoxic superoxide ions formed during 
radiotherapy into less harmful oxygen containing compounds 44,155,157,177,179,183,186. 
 
The aim of this research was to test whether an association could be found between 
variation in a gene (or multiple) and the SPADI score (as a measure of tissue damage). 
This was achieved by genotyping the participant cohort for genetic variation at SNP 
sites within these genes, and then statistically analysing the cohort genotyping results 





2.2  Materials and methods 
This study was an observational pilot study, utilising a cross-sectional design, with 
candidate gene genetic association analysis as the primary outcome. The study 
followed the working genetic research paradigm, whereby a causal and quantifiable 
link was presumed to exist in the genotype-to-phenotype disease pathway at specific 
single loci. 
 
Reporting of findings was done in alignment with STrengthening the Reporting of 
Genetic Association (STREGA) guidelines as described by Little et al. (2009) 187, 
which is an extension of the STrengthening the Reporting of OBservational Studies in 
Epidemiology (STROBE) statement 187. 
 
2.2.1  Participants 
All participants were previously identified and recruited from the parent study (HREC 
312-2012). All biological samples and questionnaire results had been collected in the 
main study prior and have been used to form this sub-study. During the parent study, 
352 patients were recruited and these were suitable for inclusion in this study. 
 
The inclusion criteria consisted of females who had undergone one, or a combination 
of surgery, RT, CT and other forms of treatment for breast cancer in the range of the 
last one to six years at the Oncology Clinic of the Groote Schuur Hospital (GSH, Cape 
Town). Participants were recruited at their annual follow-up clinic visit. The participants 
were recruited from the Mixed Ancestry population, as this is the largest population 
group within the catchment area of the Western Cape, South Africa. This population 
is genetically diverse, with a genetic background suggested to widely contain four 
major distinct groups, Europeans, South Asians, Indonesians, Xhosa, and many more 
in smaller proportions. This group comprises 8.9% of South Africans as of the 2011 
census 188,189. All participants in the study were provided with a participant information 
form (Appendix A) and written informed consent (Appendix A) was obtained from each 
participant once it was acknowledged that they understood what was required of them. 






In order to minimise the risk of confounding factors participants were excluded from 
this study if they were younger than 18 years of age, had a history of shoulder or neck 
pathology prior to diagnosis of breast cancer, have had a diagnosis of any connective 
tissue disorders or any other systemic diseases believed to be associated with 
shoulder pathology such as rheumatoid arthritis, systemic lupus erythematosus, 
hyperparathyroidism, renal insufficiency, diabetes mellitus and familial 
hypercholesterolemia. This information was self-reported or available from medical 
records. 
 
2.2.2  Ethics 
This study was approved by the Research Ethics Committee of the Faculty of Health 
Sciences within the University of Cape Town, South Africa. All research was 
performed in adherence to the principle of the World Medical Associations Helsinki 
Declaration (1964) 190. This included ensuring security of data, informed consent for 
participants and ensuring participant anonymity (Appendix B). 
 
2.2.3  Clinical variables and patient reported outcome measures  
Participants were asked to complete a validated SPADI questionnaire, a patient 
recorded outcome measure (PROM) with two domains, pain, disability and a 
lymphoedema questionnaire 75. The SPADI questionnaire contained two sections, pain 
and disability. The pain section had five questions, with a range of 1-10. One was 
described as no noticeable pain completing everyday tasks, whilst ten was described 
as the worst pain imaginable. The section on disability had eight questions, range 1-
10, with an answer of one indicating no difficulty at all completing everyday tasks, 
whilst 10 is impossible without assistance. The answers from these questions were 
combined into an overall SPADI score. 
 
SPADI scores were used to group patients into the case/control groups for association 
testing. A score below a threshold SPADI score, 30 out of 130, was considered to be 
the controls, with little to no abnormal post treatment sequelae. This is described in 




bands which were used in the statistical analysis. The SPADI questionnaire, and other 
data collection documents are included in Appendix B.  
 
All clinical variables were extracted from medical records, and transferred onto a 
source document before being captured onto a REDCap database, a secure data 
recording software platform hosted by the University of Cape Town (Research 
Electronic Data Capture, 191). 
 
Table 2.2.1 – Participants categorised into bands of shoulder pain and disability index score 
Groups Groups Total SPADI score, 0-130 SPADI category 
Control Low 0-29 Little or no pain/disability 
Case Middle 30-49 Mild to moderate pain/disability 
Case  High 50-130 Moderate to severe pain/disability 
Patients were stratified into cases and controls, and into low, medium and high groups. Testing was 
performed on both sets of category. 
Abbreviations: SPADI, shoulder pain and disability index. 
 
2.2.4  DNA extraction 
Approximately 4.5 ml of venous blood was taken from each participant by 
venepuncture in a forearm vein and collected into an ethylenediaminetetraacetic acid 
(EDTA) vacuum container tube. The tubes were kept on crushed ice and transferred 
into appropriately labelled cryo-storage boxes to the University of Cape Town 
Department of Human Biology (University of Cape Town, Anzio Road Observatory, 
Cape Town, South Africa) by the research assistant.  
 
The whole blood samples were then immediately stored at -20 C until DNA extraction 
would be performed. DNA extraction was performed by a standard salt-precipitation 
method as described by Lahiri et al. (1991) and modified by Mokone et al. (2005) 





2.2.5  Single nucleotide polymorphism selection and genotyping  
Within the literature review, seven SNPs within four candidate genes of were 
identified, and details were confirmed using the genetic databases of the National 
Centre for Biotechnology Information (NCBI, ncbi.nlm.nih.gov) and the European 
Bioinformatic Institute (EBI, www.ebi.ac.uk). Preference was given to SNPs with a 
MAF of >0.05. SNPs were either functional or regulatory variants. SNP nomenclature 
is in accordance with NCBI guidelines and full details of each SNP under 










Table 2.2.2 – A list of candidate genes, gene products, and the single nucleotide polymorphism sites 




























































* - Some SNPs have flipped chromosomal locations on older/newer genome assembly constructs (older 
- RefSeqGene, newer - GRCh38.p12). As such, the assayed nucleotide is the complement of the 
reported SNP nucleotide. For the purposes of this study, RefSeqGene nomenclature is used to remain 
consistent with the majority of literature reports, which used the RefSeqGene. 
 
Abbreviations: SPADI, shoulder pain and disability index; SOD2, superoxide dismutase; XRCC1, x-ray 
repair cross-complementing protein; ATM, ataxia telangiastica mutated; TGF-ß, transforming growth 
factor beta; BER, base excision repair; SNP, single nucleotide polymorphism; AKA, also known as. 
 
Three SNP sites within TGF-ß were chosen; the first is rs1800469, c.509 C>T, which 
prevents regulating factors binding to the UTR, and increases amount of TGF-ß 
protein produced 153. The second SNP site was rs1800471, c.74 G>C a functional 




tissue injury 194. The final SNP was rs1800472, c.788 C>T, a SNP which is frequently 
investigated alongside rs1800469 195. 
  
Within the ATM gene, two SNP sites were chosen; firstly rs1800058, c.4258 C>T, 
linked to severity of RT effect post breast cancer treatment 178,196. Then rs1801516 
c.5557 G>A, similarly linked to tissue response 50. One SNP site within XRCC1 was 
chosen, rs25487 c.1196 A>G and finally one SNP site within SOD2 rs4880 c.47 C>T, 
both linked to tissue response after breast cancer treatment 158,159,166,197,198. 
 
Genotyping performed using TaqMan (Applied Biosystems, Foster City, California, 
USA) allelic-discrimination assays. The platform used was the Thermo Fisher 
QuantStudio Five real-time Polymerase Chain Reaction (PCR) system (Thermo 
Fisher, Waltham, Massachusetts, USA), using 96-well PCR places with Thermo Fisher 
reagents. These reagents had allele specific probes (sequences available from 
manufacturer on request) targeting the candidate SNPs. The PCR master mix was 
also provided from Thermo Fisher PCR, containing Taq DNA polymerase, dNTPs and 
all reaction component except for primers and template DNA. These were used 
according to manufacturer guidelines in a final reaction volume of 8 μl. Final reaction 
mixture was as follows: TaqMan PCR mastermix – 4 μl (containing ampliTaq DNA 
polymerase), H20 – 2.85 μl, TaqMan probe and primer mix – 0.15 μl, DNA template – 
1 μl. 
 
 The standard PCR cycling procedure was; 30 second hold at 60 ˚C, followed by 40 
cycles at 95 ˚C for 15 seconds and 60 ˚C for 1 minute, with a 30 second hold step at 
60 ˚C at the end. Genotypes were determined by endpoint fluorescence and alleles 
called automatically by the QuantStudio software provided as part of the previously 
inventoried QuantStudio system. Where the software was not able to automatically 
call a result, alleles were called manually or flagged as erroneous results manually in 
the software. For standard quality control and to minimise risk of erroneous results 
every 96-welled PCR plate setup, included negative control (no DNA present) and 





All preparatory laboratory work and genotyping assays took place within the Division 
of Exercise Science & Sports Medicine facility, Department of Human Biology, Faculty 
of Health Sciences, University of Cape Town. 
 
 
2.2.6  Data management 
Patient data were managed using the REDCap software suite to ensure adequate data 
security 191. This software suite also allowed for quality control of input, using a 
redundant call/input system for data entry. Databases were stored in a password 
protected form, with patient information protected using a Study ID no. system to 
ensure anonymity. captured data input was checked for validity by a separate 
independent data capturer. 
 
2.2.7  Sample size 
A power calculation was used to determine the appropriate sample size required to 
find effects of a given odds ratio at acceptable statistical power. This was performed 
using the Genetic Association Study Power Calculator (J. Johnson, University of 
Michigan, USA 199). 
 
Determining an accurate baseline prevalence for use in the power calculation was 
difficult to determine, as the majority of studies are relatively small, use different 
populations and different methodologies. Based on a rough estimation on a number 
of the previous studies, a 30% risk of significant shoulder pain and/or disability was 
used. 1,3,72–78.  
 
Using an accepted significance level of 5% , an additive genetic model, and assuming 
minor allele frequencies of ≥0.1 it was shown that a sample size of n=343 is sufficient 
to detect an OR (genotype relative risk) of ≥1.7 at 80% power. 
 
2.2.8  Statistical analysis 
Statistical analysis was performed using R-Project v 3.4 (R Foundation for Statistical 
Computing, www.r-project.org). Seven SNPs in five genes were included in the current 




risk of confounding error in candidate genetic studies, the genotyping Hardy-Weinburg 
equilibrium (HWE) testing was performed to determine if any of the measured SNP’s 
deviated significantly from HWE. HWE testing via chi squared test requires the 
presence of all genotype combinations present in the sample, where this was not 
possible and where noted, Fishers exact test was used. 
 
SPADI scores were corrected to a range of 0-100 for testing purposes, and were then 
summarised using mean and standard deviation, with median and interquartile ranges 
used when appropriate. Plots were constructed to show the results. The Mann-
Whitney test was used to assess the difference in the SPADI score between cases 
and controls. Statistical analysis was performed using chi-square test of independence 
for categorical variables and unpaired t-test for continuous variables. A logistic 
regression analysis was conducted in order to adjust for age and determine if age was 
associated with the development of mid-to-high SPADI score. The R-Project package 
“dlpyr” was used (https://dplyr.tidyverse.org/) 
 
Two-way analysis of variance (ANOVA) was performed to assess whether any of the 
genotypes for various SNPs was significantly associated with SPADI score. The study 
population (n=326, from total study of 343, minus 17 samples with no data collected) 
is above the minimum required number of samples as determined by the ANOVA 
calculator (The Australia and New Zealand Melanoma Trials Group 200), so an ANOVA 
test was used. ANOVA was used as it is highly robust to skewness, especially when 
large sample sizes are used. Additionally, ANOVA was used because the independent 
variable (genotype) had more than three levels while the continuous variable (SPADI 
score) was continuous. Following the study power calculation, normality was assumed 
through the group. Two-way ANOVA was chosen to take into account the association 
between group (case vs. control) with the SPADI score. Haplotypes were inferred and 
used to test for possible genotype interaction effects. 
 
Pairwise post-hoc comparisons were performed following the two-way ANOVA to 
assess the pairs that are significantly different from each other (Bonferroni correction 
was used to adjust for multiple comparisons). Significance was accepted at p<0.05 













3.1  Participant demographic and clinical characteristics 
Table 3.1.1 describes the clinical information and participant characteristics recorded 
during the interview. Race was self-reported, and age was as at the time of consent, 
not at time of questionnaire completion. Age was significantly higher in the control 
group compared to the case group.  
 
Table 3.1.1 – Descriptive statistics for the study participants, stratified by case or control group.  
 Characteristic Level Case group Control group p value Test 
Group 
Control 273 (100) 0 (0)  
Independent 
sample t-test 
Case 0 (0) 70 (100)   
Age at surgery, 
(years)   
53.43 ± 0.3 50.66 ± 0.2 0.14 
SPADI score   7.02 ± 8 51.06 ± 17 <0.001 
Race 
Black 37 (14) 13 (19)  
Mixed 
Ancestry 
215 (79) 54 (77)  
White 21 (8) 3 (4)   




9 (3) 0 (0) 0.195 
Fishers exact test 
Left 138 (51) 41 (59)   






47 (17) 9 (13) 0.788 
Chi2 
I 52 (19) 14 (20)   
II 119 (44) 34 (49)   






45 (17) 7 (10.0) 0.087 
Fishers exact test 
No 33 (12) 4 (6)   








26 (10) 0 (0) <0.001 
Chi2 
No 221 (81) 52 (74)   
Yes 26 (10) 18 (26)    
Data reported as frequency (%) or mean ± SD. Age and race were self-reported at time of interview. 
Significant p values are highlighted in bold. Tumour grade assessed by nuclear grading system 201. 
Missing or incomplete data could be due to patient consenting, but not completing data collection, 
patient leaving study centre prior to data collection, or due to incomplete medical records. 






3.2  Shoulder pain and disability index scores 
Figure 3.2.1 shows that the SPADI score distribution for both controls and cases were 
skewed to the right or positively skewed. A total of 79 participants had a SPADI score 
of zero, which indicates that no pain or disability symptoms were reported by these 
participants (SPADI=0, n=79). This is expected in clinical research, partly due to the 
subjective nature of pain reporting. SPADI score data was missing for 23 participants. 
The median SPADI scores for the controls were heavily skewed towards lower SPADI 
score, as expected (median = 3.8). 
 
 
Figure 3.2.1 – The distribution of total shoulder pain and disability index scores amongst testing 
population, with control on the left side and case in the right side. Histogram breaks of 12 were used. 
Participants given as count. A – control group, B – case group. Interquartile ranges, minimum and 






3.3  Age as a predictor of SPADI score 
Table 3.3.1 displays the results of an initial logistic regression model using age at 
consent as a potential risk factor for mid-to-high SPADI score. Error! Reference 
source not found. displays the age data from Table 3.3.1 in a box-whisker plot to 
indicate the arithmetic values for the participant groups. When these data was used in 
the logistic regression model, it was found that for every additional year of age, the log 
odds of having low SPADI score increases by 0.034. The p-value indicates that age is 
statistically significant (p<0.01) in predicting whether the participant will have a low 
SPADI score. 
 
Table 3.3.1 – Logistic regression analysis comparing participants age at consent to SPADI score. 
Group Minimum 1st quarter Median Mean 
3rd  




25.4 46.6 53.9 53.6 61.4 74.5 30 
Control 
group, yrs 
25.4 48.1 55.6 54.4 61.4 74.5 26 
Case group, 
yrs  
32.8 42.3 49.6 50.7 58.6 71.3 4 
      
Predictor Odds ratio 
Standard 
error z value p value 
Age, yrs* 0.0342 0.0128 2.68 <0.01 
Participant age was used as independent variable, control and case group as conditions, with SPADI 
score as dependant variable. Values for age are given in number of years. No data given as a count. 
Significant values are highlighted in bold.  







Figure 3.3.1 - Box-whisker plot showing the distribution of age in all study participants (top), and 
separated into the case and control groups (middle and bottom bar). The total bar length is range, the 
boxes are the interquartile range, the black line bisecting the box is the median, and the black dots 









Table 3.4.1 reports the data for the distribution of genotypes throughout the cohort, as 





Table 3.4.1 - Genotype and minor allele frequency distributions, and Hardy-Weinburg equilibrium tests.  
Polymorphism Genotype Controls (n=273) Cases (n=70) p value 
Transforming growth 
factor ß No data 
110 (40) 25 (36) 
0.924   CC 57 (21) 19 (27) 
 rs1800469 CT 99 (36) 24 (34) 
c.1347 C>T TT 7 (3) 2 (3) 
  HWE  <0.001  
  T Allele 0.35 0.31   
Transforming growth 
factor ß No data 
55 (20) 12 (17) 
0.718   CC 214 (78) 56 (80) 
rs1800472 CT 4 (2) 2 (3) 
  TT 0 (0) 0 (0) 
c.788 C>T HWE 
0.609   
  Fishers exact test 
  T Allele 0.02 0.02   
Superoxide 
dismutase 2 No data 
75 (28) 17 (24) 
0.045   CC 74 (27) 20 (29) 
rs4880 CT 98 (36) 19 (27) 
c.47 C>T  TT 26 (10) 14 (20) 
  HWE 0.721   







Polymorphism Genotype Controls (n=273) Cases (n=70) p value 
Xray repair cross 
complementing 
protein 1  
No data 73 (27) 17 (24) 
0.650   AA 116 (43) 29 (41) 
rs25487  AG 68 (25) 20 (29) 
c.1196 A>G GG 16 (6) 4 (6) 
  HWE 0.205   
  G Allele 0.25 0.26   
Ataxia-telangiectasia 
mutated No data 
68 (25) 15 (21) 
0.319   CC 200 (73) 53 (76) 
rs1800058 CT 5 (2) 2 (3) 
c.4258 C>T TT 0 (0) 0 (0) 
  HWE 
0.642   
  Fishers exact test 
  T Allele 0.01 0.02   
Ataxia-telangiectasia 
mutated No data 
53 (19) 13 (19) 
0.393   GG 196 (72) 52 (74) 
rs1801516 AG 23 (8) 5 (7) 
c.5557 G>A AA 1 (0) 0 (0) 
  HWE 0.826  
  A Allele 0.06 0.04   
Values are the number of participants in each group (n) with percentages of total in parentheses. 
Samples were genotyped at the following sites: rs1800469 c.1347 C>T TGF-ß, rs1800472 c.788 
C>TGF-ß, rs4880 c.47 C>T SOD2, rs25487 c.1196 A>G XRCC1, rs1800058 c.4258 C>T ATM and 
rs1801516 c.5557 G>A AT, in a Mixed Ancestry South African population. No data was used where 
either genotyping failed to produce a response, or DNA samples were not available from participant. 
Hardy-Weinburg Equilibrium via chi squared test requires the presence of all genotype combinations to 
calculate in significant numbers. Where noted, Fishers exact test was used. Significant values are 
highlighted in bold. 




3.5  Genotyping results 
For 48 patient samples, genotyping were unsuccessful for all SNPs. This complete 
unresponsiveness to testing was consistent across repeated troubleshooting 
procedure results. In addition, the genes investigated are at different loci. In total 23 
participants had missing clinical data for the SPADI scores. A total of 17 participants 
had missing data for both the questionnaire data and genotyping data and were 
therefore excluded from the analysis, which led to a final number of n=326 participants 
in the study. Table 3.5.1 shows the numbers of successful genotyped population for 
each SNP. Experimentally derived minor allele frequencies were generally in line with 
globally reported minor allele frequencies.  
 
When genotyping was unsuccessful, steps were taken to resolve the issue. The 
procedure was repeated to account for operator error, and different batches of 
reagents were used. If this failed then the assay mixture was altered to increase the 
relative amounts of the key reagents in the reaction vessel. This involved increasing 
the total reaction volume to 10 μl, and doubling the volume of the probe and DNA 
samples within the reaction vessel. Finally, to maximise the PCR amplification, the 
number of PCR cycles were increased to increase the chance of a successful reaction. 
 
















TGF-ß rs1800469 208 135 61% 33.9 36.0 
TGF-ß rs1800471 N/A N/A N/A N/A N/A 
TGF-ß rs1800472 276 67 80% 0.0 1.0 
ATM rs1800058 260 83 76% 1.3 1.0 
ATM rs1801516 277 66 81% 5.4 7.0 
SOD2 rs4880 251 92 73% 39.2 41.0 
XRCC1 rs25487 253 90 74% 25.3 26.0 
Reported allele frequencies were taken from 1000 genome database, consisting of 2,504 individuals 
across 26 populations and were not specific to the studied population. Samples were genotyped at 
the following sites: rs1800469 c.1347 C>T TGF-ß, rs1800472 c.788 C>TGF-ß, rs4880 c.47 C>T 
SOD2, rs25487 c.1196 A>G XRCC1, rs1800058 c.4258 C>T ATM and rs1801516 c.5557 G>A AT, 
in a Mixed Ancestry South African population. 





3.5.1  Rs1800471 - TGF-ß 
The real-time PCR procedure for this polymorphism produced an unacceptably low 
assay success rate. Attempts were made to modify and repeat using appropriate 
troubleshooting procedures, which were unsuccessful. Based on this failure, the 
generated data were excluded from analysis as the data was not of high enough 





3.6  Hypothesis testing – case vs control 
Genotyping data, shown in Table 3.5.1, were analysed with a two-way analysis of 
variance test to indicate if any of the results show a statistically significant association 
to severity of symptoms.  
 
When the total cohort was tested for association between genotype and SPADI score, 
there was no evidence found within this study to support an association in any 
polymorphism, as shown in Table 3.6.1. 
 
Table 3.6.1 – Inferred haplotype analysis as a proxy for gene-gene interactions was performed on; 
rs1800469 c.1347 C>T TGF-ß, rs1800472 c.788 C>TGF-ß, rs4880 c.47 C>T SOD2, rs25487 c.1196 
A>G XRCC1, rs1800058 c.4258 C>T ATM and rs1801516 c.5557 G>A ATM polymorphisms in a South 
African population. 
Haplotype     
Gene 1  SNP 1 Gene 2 SNP 2 Gene 3 SNP 3  Df Sum Sq Mean square F value Pr, >F 
TGF-ß  rs1800469  TGF-ß  rs1800472   4 1786 447 0.904 0.463 
TGF-ß  rs1800469  SOD2 rs4880   8 3344 418 0.846 0.563 
TGF-ß  rs1800472 SOD2 rs4880   5 1449 290 0.586 0.711 
TGF-ß  rs1800469  XRCC1 rs25487   8 2592 324 0.656 0.73 
TGF-ß  rs1800472 XRCC1 rs25487   1 12 12 0.024 0.877 
SOD2 rs4880 XRCC1 rs25487   7 2919 417 0.844 0.552 
TGF-ß  rs1800469  ATM rs1800058   4 880 220 0.445 0.776 
TGF-ß  rs1800472 ATM rs1800058   1 126 126 0.254 0.615 
SOD2 rs4880 ATM rs1800058   4 2338 585 1.18 0.319 
XRCC1 rs25487 ATM rs1800058   4 295 73.6 0.149 0.963 
TGF-ß  rs1800469  ATM rs1801516   4 1424 356 0.72 0.579 
SOD2 rs4880 ATM rs1801516   3 1761 587 1.19 0.315 
XRCC1 rs25487 ATM rs1801516   3 1404 469 0.947 0.419 
ATM rs1800058 ATM rs1800058     1 461 461 0.932 0.335 
TGF-ß  rs1800469  SOD2 rs4880 XRCC1 rs25487 8 2279 285 0.576 0.797 
TGF-ß  rs1800469  SOD2 rs4880 ATM rs1800058 2 101 50.7 0.103 0.902 
SOD2 rs4880 XRCC1 rs25487 ATM rs1800058 1 0 0.1 0 0.992 
TGF-ß  rs1800469  SOD2 rs4880 ATM rs1801516 3 401 134 0.27 0.847 
TGF-ß  rs1800469  XRCC1 rs25487 ATM rs1801516 2 1652 826 1.67 0.19 
SOD2 rs4880 XRCC1 rs25487 ATM rs1801516 1 28 28.2 0.057 0.811 
     Residuals 
 12 470 39.2  
Abbreviations: SNP, single nucleotide polymorphism; DF, degrees of freedom; SPADI, shoulder pain 




3.7  Hypothesis testing – low, medium, high case testing 
In addition to the ANOVA testing of the cohort case vs control, testing was also 
performed on the case group, subdivided into low case (SPADI 0-29), medium case 
(SPADI 30-49) and high case (SPADI 50-100). This represents a low SPADI 
phenotype through to a stronger SPADI phenotype.  
 
Within the low SPADI phenotype group, the haplotype of rare alleles at rs4880 and 
rs1800058 was strongly associated (p<0.01) with being in the low SPADI score group. 
None of the tested allele combinations were significantly associated with risk of 







Table 3.7.1 - Inferred haplotype analysis as a proxy for gene-gene interactions was performed on; 
rs1800469 c.1347 C>T TGF-ß, rs1800472 c.788 C>TGF-ß , rs4880 c.47 C>T SOD2, rs25487 c.1196 
A>G XRCC1, rs1800058 c.4258 C>T ATM and rs1801516 c.5557 G>A ATM polymorphisms in a South 
African population. 
Low SPADI  
Haplotype       
Gene 1 SNP 1 Gene 2 SNP 2 Gene 3 SNP 3 Df Sum Sq Mean Square F Value Pr (>F) 
TGF-ß  rs1800469  TGF-ß  rs1800472   3 267 89.1 1.53 0.208 
TGF-ß  rs1800469  SOD2 rs4880   8 150 18.7 0.322 0.957 
TGF-ß  rs1800472 SOD2 rs4880   4 136 34.1 0.587 0.673 
TGF-ß  rs1800469  XRCC1 rs25487   7 534 76.3 1.31 0.247 
TGF-ß  rs1800472 XRCC1 rs25487   1 48 48.5 0.83 0.362 
SOD2 rs4880 XRCC1 rs25487   7 628 89.8 1.54 0.156 
TGF-ß  rs1800469  ATM rs1800058   3 331 110 1.9 0.132 
TGF-ß  rs1800472 ATM rs1800058   1 0 0.04 0.001 0.978 
SOD2 rs4880 ATM rs1800058   4 1011 252 4.35 >0.01 
XRCC1 rs25487 ATM rs1800058   2 103 51.7 0.889 0.413 
TGF-ß  rs1800469  ATM rs1801516   3 66 21.8 0.376 0.771 
SOD2 rs4880 ATM rs1801516   3 313 104 1.79 0.150 
XRCC1 rs25487 ATM rs1801516   3 286 95.2 1.64 0.182 
ATM rs1800058 ATM rs1801516     1 219 219 3.78 0.054 
TGF-ß  rs1800469  SOD2 rs4880 XRCC1 rs25487 8 770 96.2 1.66 0.113 
TGF-ß  rs1800469  SOD2 rs4880 ATM rs1800058 1 11 10.8 0.187 0.666 
SOD2 rs4880 XRCC1 rs25487 ATM rs1800058 1 2 1.67 0.029 0.866 
TGF-ß  rs1800469  SOD2 rs4880 ATM rs1801516 2 169 84.5 1.45 0.237 
TGF-ß  rs1800469  XRCC1 rs25487 ATM rs1801516 1 0 0.34 0.006 0.939 
SOD2 rs4880 XRCC1 rs25487 ATM rs1801516 1 56 55.5 0.955 0.330 







Haplotype      
Gene 1 SNP 1 Gene 2 SNP 2 Gene 3 SNP 3 Df Sum Sq Mean Square F Value Pr (>F) 
TGF-ß  rs1800469  TGF-ß  rs1800472   1 0.6 0.59 0.015 0.904 
TGF-ß  rs1800469  SOD2 rs4880   5 111 22.2 0.565 0.725 
TGF-ß  rs1800469  XRCC1 rs25487   1 0.2 0.2 0.005 0.944 
SOD2 rs4880 ATM rs1800058   2 33.7 16.9 0.43 0.660 
TGF-ß  rs1800469  ATM rs1800058   2 60.5 30.2 0.772 0.484 
TGF-ß  rs1800469  ATM rs1801516     1 15.7 15.7 0.401 0.538 
TGF-ß  rs1800469  SOD2 rs4880 XRCC1 rs25487 1 97.6 97.61 2.49 0.141 
     Residuals   2371 2371 2371  
 
High SPADI 
Haplotype       
Gene 1 SNP 1 Gene 2 SNP 2     Df Sum Sq Mean Square F Value Pr (>F) 
TGF-ß  rs1800469  SOD2 rs4880   3 163 54.3 0.252 0.859 
TGF-ß  rs1800469  XRCC1 rs25487   3 356 119 0.55 0.659 
SOD2 rs4880 XRCC1 rs25487     3 62.2 20.7 0.096 0.961 
     Residuals   2371 2371 2371  
Abbreviations: SNP, single nucleotide polymorphism; DF, degrees of freedom; SPADI, shoulder pain 





3.8  Summary 
This study investigated the hypothesis that genetic variation in TGFß, ATM, SOD2 and 
XRCC1 genes may be associated with the inter-patient variation of SPADI symptoms 
observed after cancer treatment 36,155,183. The underlying causative factors of these 
symptoms are not understood, and as the population of breast cancer survivors is 
likely to increase with improved medical care, it is likely that the prevalence of these 
symptoms will increase in the near future without intervention 1,3,16,79,81,82. 
 
A literature review was conducted to compile and assess previously published data 
into incidence and prevalence of musculoskeletal and connective tissue dysfunction 
in cancer survivors 1,3,168. From this, a list of potential candidate risk alleles were 
chosen at specific SNP sites within genes that function in the pathways of inflammation 
and wound healing, which lead to fibrosis 44,99,178–180,115,118,119,153,155,156,176,177. Some of 
these candidate alleles might have only been present in a low frequency in the 
population, this represented an unknown factor due to the lack of genetic data on the 
studied populations. In addition the genetic component of one gene is unlikely to have 
a large affect 183. The hypothesis was that within the population of breast cancer 
survivors, the genotype of these candidate alleles collectively would be associated 
with SPADI score. It is now possible to interpret the results to see if this hypothesis 
can be accepted, although proving causality is beyond the scope of this study.  
 
In the next section, novel findings of this study will be linked to the wider biological and 
clinical environment. Possible future pathways for research and treatment will be 
explored, to build upon the results of this study, and other studies in the literature, and 
the strengths and limitations of this study will be reported, in order to ensure that 










4.1  Novel findings 
 
4.1.1  Demographics 
When participant age was compared with symptom severity, it was found that the 
arithmetic age mean for the cases and controls were different, with an average age of 
54.4 years in the control group vs an average age of 50.7 years in the case group. 
This indicates that younger participants were more likely to have moderate-to-severe 
symptoms than older participants, this finding is in agreement with many other reports 
of the effects age in similar conditions 202–204. There is currently no consensus for the 
possible reasons. It is possible that there is a biological cause, but it is also possible 
that there are confounding factors. There may be a difference between age groups in 
the propensity to either report, or to not report, the same level of pain and disability. 
There may also be socio-economic factors, individuals with high levels of access to 
care may be diagnosed and treated at an earlier stage, requiring less severe 
treatment, and therefore be more likely to survive with minor symptoms to an older 
age. 
 
4.1.2  Single nucleotide polymorphisms 
When the allele frequencies were compared for cases vs controls in Table 3.4.1, the 
frequency of minor alleles for SOD2 rs4880 (C>T) was found to be significantly 
deviated from the normal distribution. When allele frequencies in the case and control 
groups were calculated, it was found that the T allele is over-represented in the case 
group compared to the control group, with a frequency of 0.44 vs 0.38 respectively.  
 
The SOD2 gene, and the rs4880 genetic polymorphism site, were chosen for 
investigation in this study following associations with pathology reported in several 
papers 159,184,186,198. The genetic dimorphism at rs4880 is a C>T change, which confers 
a codon shift from alanine to valine. There is debate in the literature as to the impact 
of the change of alanine to valine at codon 16, which functions in the mitochondrial 
targeting sequence (MTS), which facilitates the transport of the precursor enzyme 
across the mitochondrial membranes 160,205,206. In one paper, that alanine form of the 




form 186,206,207. Increased SOD2 activity is associated with an anti-oxidative, anti-
fibrotic effect in most papers, and this would be supported by the finding of an 
increased minor allele frequency of T alleles in the case group. There are conflicting 
reports however, as one study has reported 30% higher activity in CT or TT SOD2 vs 
CC at codon 16 208. In addition, a study of patients undergoing RT for prostate cancer 
found that CT, but not CC or TT genotypes, was associated with 8% increased risk of 
severe late rectal bleeding 184. Whilst a general trend towards an increase of function 
of SOD2 seems to be associated with a beneficial increased anti-oxidant functionality, 
more investigation will clearly be needed to elucidate the effect of variation at rs4880. 
 
4.1.3  Inferred haplotypes 
No intragenic inferred haplotypes were found, however, when inferred haplotypes 
were constructed as a proxy for gene-gene interactions, an allele combination was 
identified between SOD2 rs4880 (C>T) and ATM rs1800058 (C>T) and the low SPADI 
group, indicating that the interaction between the variant forms of these gene is 
associated with a low SPADI score in this sample population. 
 
These two specific polymorphisms were selected for genotyping in this study because 
both of the gene products interact in pathways that can modulate the formation of 
fibrotic tissue. Because of this, it was anticipated that in an individual with multiple rare 
genotypes, we would possibly see an amplified effect of the individual polymorphisms. 
As previously mentioned, rs4880 C>T is understood to contribute to a decrease of 
function of SOD2, so with this model of function, we would possibly not have expected 
the rare allele to be statistically inferred in relation to low SPADI score 44,160,205. When 
interpreting these results, it is important to remember the limits of this study, the 
conflicted nature of reports, and the clear need for more investigation of the function 
of SOD2 and genetic variation within. 
 
The genetic variation rs1800058 in ATM has been investigated in several 
radiosensitivity studies, including in other cancers such as prostate cancer 178,209,210. 
A large proportion of genetic variants in ATM (70%) are reported to be truncating or 
otherwise deleterious, and therefore linked with lower enzymatic activity 178,211. Certain 




178,211. Individuals with major loss of function of ATM have catastrophic vulnerability to 
ionising radiation, leading to extreme radiosensitivity 178,196,212. In the general 
European population, 0.5-1% of the population are heterozygous carriers of at least 
one ATM variant allele 211,213,214. This haplo-insufficiency is associated with increased 
sensitivity to radiation 185,211.  
 
In contrast to many of these findings in ATM, rs1800058 has been identified as having 
a protective effect from fibrosis. In a paper by Edvardsen et al. (2007) studying ATM 
allele frequencies in a population of breast cancer patients treated with RT, a decrease 
in the minor allele frequency at rs1800058 was found to be associated with an 
increasing level of adverse side effects for late radiation tissue injury, thus suggesting 
a protective effect of the rare allele. These findings are in concordance, and suggest 
that there may be a protective effect of this gene-gene interaction 178. We therefore 
recommend further investigation of these combinations in a larger case control study. 
 
Finally, there was another observation which fell below the allowed significant level, 
between rs1800058 and rs1801516 (G>A) both in the ATM gene, again with a low 
SPADI score. In the literature, rs1801516 has been investigating in a larger meta-
analysis (2000 patients in nine studies) for risk of RIF, in which presence of the minor 
allele was associated with a significantly increased risk of RIF, with high-RIF patients 
having an OR for minor allele presence of 3.19 vs 1.09 50,176,211,213. This finding 
contradicts this, as the two SNPs linked have reports of contradictory effects 
(rs1800058 variant alleles are believed to be protective, while rs1801516 variants are 
harmful). This, along with a significance level below the accepted limit, indicates that 
this finding may not be reliable, and is not suggested for further study at this stage. 
 
4.1.4  Novel findings summary 
Within this section, the observed results were explored in the context of the previously 
existing literature, and biological context. Polymorphisms within two genes, SOD2 and 
ATM, have been identified as recommended for future study, based on associations 
identified within the results. SOD2 and ATM genes both function within the biological 
processes that allow tissue to repair and return to homeostasis after cellular insult. 




been explored. These results must be taken within the overall limited strength of this 
study. Suggesting a causal link between these genetic variants and large scale effects, 
is beyond the power of this study. More research is needed, but these findings can 
suggest these variants for future study. 
 
No significant results were noted for the polymorphic sites within TGF-ß. Given that 
TGF-ß gene activity is proposed to be one of the major factors in the pathophysiology 
of radiotherapy-induced fibrosis, this was unexpected. This is a pilot study of limited 
power, and it is extremely possible that any possible associations may become 
apparent in studies of greater power. It is also possible that the many reports of TGF-
ß associations are spurious, or merely highly contextual. It is impossible to conclude 





4.2  Future research 
As discussed in the literature review, there are significant gaps in both understanding 
and treatment options of RIF and other cancer treatment related morbidities. These 
knowledge gaps exist in many areas, including the underlying biology, epidemiology 
and possible treatment options. Future research in all fields will endeavour to increase 
our ability to treat these conditions, and prevent occurrence in the first place. 
 
4.2.1  Population genetic data  
One finding of this paper is that genetic research is underrepresented in economically 
poorer populations. When attempts were made to find large-scale, comprehensive 
genetic data for the Mixed Ancestry South African population, none was found 215–217. 
The vast majority of genome-wide studies are based in European populations, and 
even within the few African population based studies, there is an unacceptable amount 
of heterogeneity in recording of descriptions, with large geographic regions being 
combined into one result 215. This issue is compounded by the genetic heterogeneity 
within the Mixed Ancestry South African population itself. This group is genetically 
diverse, with a genetic background widely containing four major distinct groups, 
Europeans, South Asians, Indonesians, Xhosa, and many more in smaller proportions 
188,215. When considering that this population accounts for up to five million South 
Africans, it is important that this imbalance is resolved, and the genomic data of this, 
and other understudied groups, especially in Africa, is compiled. Without this, these 
population groups will not be able to benefit equally from improvements in 
personalised and precision medicines. Some projects have started to improve the 
situation, such as the African Genome Variation Project (AGVP), and the Human 
Hereditary and Health (H3A) project, the latter of which is currently processing the 
genome of 70,000 participants across the continents, accompanied by detailed clinical 
information banks 215,216. 
 
4.2.2  Genomics and precision medicine 
In this study, a candidate gene approach was determined to be the most suitable 
approach. While this is currently a standard research approach, it is expected that in 




access to data analysis tools increase. Currently, the cost and complexity of running 
genome wide analysis (GWAS) makes this tool unavailable or unfeasible for many 
research teams. This is changing as technology progresses and costs are decreasing. 
As this happens, and as the impact of projects such as H3A start to produce results 
and due to the huge amount of data produced by GWAS there is also an increasing 
need for reliable analysis tools and comprehensive review publications in genomics 
119,218–220. One example is the H3A’s recently developed SNP genotyping array, based 
on the African data from the 1000 genome project, the AGVP project, and several 
smaller projects, with 1.7 million SNP’s chosen as base content to cover the African 
genome, and ~700,000 SNPs of specific interest, requested by project collaborators 
in H3A 221. This project is backed through funding to upgrade testing sites across the 
continent to include high throughout sample processing 221. Consisting of 500 
members, in 30 out of the 55 African countries, H3A has the potential to contribute to 
a generational shift in genomic research in South Africa and the wider continent. 
 
4.2.3  Treatments 
When the genetic and biological causes of SPAD are better understood, treatment 
regimens can be tested and eventually incorporated into the treatment regimens. 
Alongside treatment, preventative measures will also be introduced, such as 
modulation of breast cancer treatment protocols to minimise the potential risk in those 
who would be more susceptible to fibrosis 222.  
 
Within the literature review, fibrosis has been heavily suggested as being one of the 
key pathological processes in post cancer treatment sequelae. Fibrosis is heavily 
driven by inflammatory factors, and therefore it is likely that targeting the inflammatory 
process will feature in future treatment plans, anti-inflammatory therapies could 
prevent large scale accumulation of inflammatory cells in the area, halting the fibrotic 
process before it begins. As previously noted, the lack of findings within the TGF-β 
gene was disappointing, due to the many reported associations in the literature 
41,47,115,142,161,181,197,223. Despite this, targeting of the TGF-β axis directly has been one 
of the first studied as a potential treatment for fibrotic disease and RIF 143. Due to the 




has proven difficult to achieve 128–131. It is important to remember that any large scale 





4.3  Strengths and limitations 
As with all research, this dissertation has areas of strength and areas of limitation.  
 
4.3.1  Demographics and clinical characteristics  
The demographic and clinical information for the cohort was limited in several ways. 
Patients were recruited from the Mixed Ancestry population of South Africa (self-
reported). Due to this, bioinformatic databases frequently lacking information on the 
expected allele frequencies of this group. As a result of this, there was no reliable 
estimation of expected minor allele frequencies available. 
 
In addition, participants were not subdivided into groups based on treatment modality. 
All participants had some combination of one, or multiple treatments, with the main 
modalities of RT, CT, HT and surgery. Ideally this study would have isolated 
participants by treatment modality group, in order to exclude any effect that different 
treatments might have upon the results. Unfortunately, as most patients had at least 
two modalities this was not possible, and there was already a consideration that had 
to be taken as to the reduction in study power by reducing the cohort size by that 
degree. 
 
4.3.2  Data collection 
Accurate and precise data collection is essential to any study. Much of the data 
collected from participants was self-reported. Self-reported data is not inherently a 
weakness in appropriate uses, for example when assessing subjective pain levels. 
However, use of self-reported data such as medical history is generally undesirable, 
and prone to inaccuracies due to cognitive flaws and memory loss. This was 
unfortunately unavoidable in some cases, as detailed, accurate and accessible 
medical history is not a guarantee for many individuals. 
 
The amount of missing data for collected data was significant. This can be attributed 
to a number of factors, including the large number of recorded variables, the socio-
economic factors of the population studied, and shortcomings within the South African 




were included where possible, therefore a complete case analysis was not used. As 
this data was collected prior to this study, this shortcoming could not be addressed 
within this study. Despite this, the statistical tools and significance levels required for 
this study ensure that results are reliable despite this. 
 
Within the sample, 79 participants reported a SPADI score of zero, indicating that they 
felt no pain or disability, at the time of recording (one-year post surgery). The 
questionnaire used to provide this score was the SPADI questionnaire, a self-reported 
questionnaire completed by all participants. As this question-based testing is highly 
subjective, there is a possibility that an individual’s inclination towards reporting 
disability or changes in quality of life as a matter of personal preference could be 
skewing the results. This introduces a degree of subjectivism and therefore reduces 
the accuracy and precision of the measured variables within the questionnaire results. 
The questionnaire is partially retrospective, requiring recall and memory of pain and 
disability from the year prior to the testing interview, which is somewhat unreliable, as 
memory of pain can be unreliable. There is also the possibility of cultural differences 
between the researchers and population, with respect to what an individual might 
describe as ‘hardship’ or ‘disability. Finally, while there was provision for non-English 
speakers, there may have been inadvertent ambiguity in the language used by both 
researchers and participants, including those for whom English is not the first 
language. This subjective recording of symptom severity from the questionnaires was 
used to designate a control group which either suffered no or little SPADI symptoms. 
This is a noted difficulty within case/control studies. 
 
One method of improving future research would be to develop a more objective 
method of measurement of symptom severity for future research into post-cancer 
treatment late tissue morbidity. This could be in the form of a battery of impartial 
measurement of symptoms against objective measurement of pain and disability 
severity. Another possibility could be staggered screenings over the time period of 
recovery (e.g every three months up to two years post treatment) in order to provide 






4.3.3  Methodology 
During the laboratory testing, the genotyping success rates for several of the assays 
were low. This was evident during the analysis as a significant number of samples 
failed to be genotyped at all polymorphisms studied. Low error rates are claimed by 
all manufacturers and probes have high specificity with functionally proven testing for 
the DNA sequences targeted. Despite this, the reasons for a sample failing to be 
amplified are numerous and can be difficult to determine. Molecules present within 
reagents, or in the samples themselves could hinder amplification, the problem could 
also be within the DNA samples; the DNA is either no longer intact or no longer 
responding to testing due to degradation. Regardless of the cause, repeated 
genotyping of failed samples can be known to produce false results. Because of this 
risk, samples that failed after troubleshooting (described in section 3.5) were 
discarded from further analyses. 
 
It has been acknowledged that only a relatively small number of genetic loci were 
investigated within this study, this is partly due to constraints on the project in terms of 
time and other resources. Another constraint is that this research is still a relatively 
new area of research, with fairly little published literature, which limits the number of 
candidate genetic testing targets identified within the literature. In addition, using a 
candidate gene approach limited the research to exploring only gene loci that had 
been previously investigated. These constraints are however to be expected within 
the constraints of an MSc thesis, and are intended to be taken within the context of a 
larger research body. In addition, variant loci were often identified in a drastically 
different population, commonly Caucasian, to those being tested, and as such it is 
always possible that significant genetic loci may not be relevant in a different 
population due to genotypic variation. 
 
Finally, HWE quality control was significantly breached for the rs1800469 
polymorphism. Deviation from HWE can indicate problems such as selection bias 
within the group, population stratification and genotyping errors. 
 
One area of strength is that the hypothesis focussed approach was followed. This 




review section presented research from this main study group. This body of research 
was used as basis of the review, which produced a hypothesis and aims for the 
experimental section.  
 
This provides guidelines for genetic association studies, including guidelines on ethical 
approval, patient recruitment and carrying out laboratory work. The statement also 
informs how to conduct unbiased and accurate reporting of the results, with 
transparency. Following these guidelines, multiple samples were repeated within the 
study to serve as positive and negative controls whilst blanking samples, containing 
no DNA were also included per 96 well plate run. The laboratory protocol and results 
were checked by senior team members. 
 
One of the major areas of strength of the study is the case control design. The case-
control candidate genetic association study design was conducted in accordance with 
the guidelines provided by the STREGA statement. This provides guides for genetic 
association studies, including guidelines on ethical approval, patient recruitments 
(when applicable) and carrying out laboratory work. This also includes unbiased and 
accurate reporting of the results, with transparency. Multiple samples were repeated 
within the study to serve as positive controls, and negative controls containing no DNA 
samples were also includes per 96-well plate run. All attempts were made to follow 
the principles and guidelines of the STREGA guidelines for quality control purposes. 
The laboratory protocol and results were checked by senior team members. 
 
All attempts were made to follow the principles and guidelines of the STREGA 
guidelines for quality control purposes. However, as with all novel findings, the 
associations highlighted in this study need to be investigated in greater detail, in larger 





4.4  Summary and concluding remarks 
As discussed in the first chapter, breast cancer is a common and well treated form of 
cancer. A consequence of this increased post-cancer survivor population is increased 
prevalence of cancer-treatment related conditions. These include a subset of cancer 
survivors, who develop musculoskeletal dysfunction in the shoulder and upper limb 
after having received radiotherapy (and other treatments) for breast cancer. There is 
a high degree of inter-group difference, both in the range, and severity of symptoms 
exhibited. This range in symptoms is not explained by currently available literature. 
 
In the literature review a hypothesis was developed that genetic signalling pathway 
dysfunction leading to fibrosis in these tissues could be an instigating biochemical 
cause of these symptoms. It was hypothesised that genetic variation between these 
individuals could explain why some people seem more susceptible to this fibrosis than 
others. A list of candidate influential genetic variant SNP sites was developed from 
past research, and a candidate gene genetic association study was decided upon as 
the most suitable study protocol. 
 
Table 4.4.1 – A list of the genes selected for inclusion within the study, and the specific genetic 
polymorphism under investigation. Samples were genotyped at the; rs1800469 c.1347 C>T TGF-ß, 
rs1800472 c.788 C>TGF-ß , rs4880 c.47 C>T SOD2, rs25487 c.1196 A>G XRCC1, rs1800058 c.4258 
C>T ATM and rs1801516 c.5557 G>A ATM polymorphisms in Mixed Ancestry South African population. 
Gene SNP 
TGF-ß  rs1800469  
TGF-ß  rs1800471  
TGF-ß  rs1800472 




Abbreviations: SNP, single nucleotide polymorphism. 
 
After testing, the experimental protocol for one SNP variant presented a low yield and 
data was discarded, leaving valid data for six SNPs. Statistical analysis was then 
performed on the results to determine if any results were significant.  
 
When the age at surgery was compared to self-reported SPADI scores, it was found 




older participants, which is concurrent with many similar reports 203,204. This study 
provides evidence reinforcing the previous reports. 
 
When the genotype data of the study population was directly compared to severity of 
symptoms, no single SNP was shown to be associated with symptom severity. 
However, when the allele frequencies were compared for case vs control, the 
distribution of frequency of minor alleles of rs4880 was found to be significantly 
deviated from the expected distribution. This is novel evidence suggesting that 
variation in the MTS section of ATM may be associated with the severity of an 
individual’s response to cancer treatment. 
 
When inferred haplotypes were constructed as a proxy for gene-gene interactions, a 
significant difference in haplotype distribution was found between SOD2 rs4880 and 
ATM rs1800058, while a borderline significant difference was found between ATM 
rs1800058 and ATM rs1801516. Further to the previous finding, this is additional novel 
evidence that the ATM and SOD2 genes may be linked to modulating the effects of 
cancer treatment cyto-toxicity. 
 
To summarise, this study provides novel evidence suggesting that the SOD2 and ATM 
genes, and the cyto-protective and free-radical scavenging and DNA repair pathways, 
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ADDRESS: Department of Human Biology, Level 2, Anatomy Building, Faculty of health Sciences, University 
of Cape Town, Observatory, 7925; Exercise Science and Sports Medicine (ESSM); Vincent Palotti Hospital. 
 
Invitation to participate: We are inviting you to take part in a research project in breast cancer because you 
have been treated for breast cancer in the past. . Please read the information in this letter very carefully as it 
explains the details of the project and how you could be involved. Please ask your doctor to explain anything 
that you do not understand.  Only you can decide if you want to take part and, if you choose to say no or to 
withdraw from the study at any time, it will not affect your medical treatment in any way, not now or in the 
future. 
 
What is the study about? Shoulder problems are a well-documented side effect of the treatment for breast 
cancer. Shoulder problems experienced by some women can be as mild as slightly limited movement to more 
serious conditions such as frozen shoulder. Treatments like axillary surgery or radiotherapy have been shown 
to increase the risk of developing shoulder problems but some women still develop problems if they have not 
had axillary surgery. Not all women treated for breast cancer develop shoulder complications and we do not 
know why some women do have problems and others do not. We do know that radiotherapy can change blood 
flow and cause scar tissue formation. We also know that chemotherapy sets off an inflammation reaction in 
some tissues. 
This study will be the first study to look at the proteins involved in these effects and explore how they might be 
related to shoulder pain and dysfunction. We will compare this to survivors with no shoulder problems. 
All the information for our normal bodily functions is stored in our genetic material, DNA, which is found in 
all our cells. The genetic information in the DNA which is packaged into units called genes is passed from one 
generation to the next.  
Research on genes has shown that if a small change is present in the gene(s) then it could weaken or predispose 
the body to illness. We are also doing research to find out which genes might predispose people to develop 
shoulder complications.  
Research has shown that exercises and physiotherapy can help to reverse the pain and dysfunction experienced 
by some patients. We would like to be able to identify those patients at risk of developing shoulder 











Will I get paid for taking part: You will not be paid to take part in the study. 
 
Are there any risks involved in the process: Drawing blood is a standard procedure. There may be a little 
discomfort and pain and a small risk of bruising. If you are still concerned after a few days about a study-
related injury then please contact Dr Morrell (telephone numbers are given on page 1 of this document). 
 
What benefits are there for me: There are no direct benefits from the study. This study does not aim to provide 
a cure for shoulder complications but it may provide information that will be useful in the future to understand 
what causes the complications and how to improve treatment.  
 
Do I have to take part? NO. It is entirely up to you if you want to take part in this study. You may decide that 
you do not want to take part or decide to withdraw from the project at any time. This decision will not affect 
any current treatment you may be receiving. 
 
What if I have other questions now or later about the study or my rights: If you have questions about the study 
that are not answered in these Information Sheets please ask the interviewer to answer them. If you have any 
concerns related to this project in the future you may contact: 
• the study investigators at the telephone numbers given on the first page  
•Professor Marc Blockman, Chair, UCT Human Research Ethics Committee, Faculty of Health Sciences, may 
be contacted by research subjects to discuss their rights.  










CONSENT FORM  
Date: 27/5/12   
Version: 01 
 
Project Title: Correlating clinical disease state of the shoulder after treatment for breast cancer with biomarkers 
of inflammation and angiogenesis and their associated genetic variants 
 
AGREEMENT TO PARTICIPATE 
I, _________________________, have read (or had read to me) the Information Sheet for the study named 
‘Correlating clinical disease state of the shoulder after treatment for breast cancer with biomarkers of 
inflammation and angiogenesis and their associated genetic variants’ 
My role in the study is as a research volunteer to help the investigators collect information about the proteins 
and genes that may be involved in the development of arm and shoulder complications after treatment for 
breast cancer. I understand that the purpose of this study is not to cure shoulder problems and the genetic 
information may or may not be useful in designing better ways to treat these complications in the future. My 
questions have been answered to my satisfaction in a language that I understood. By signing this consent form 
I do not waive any of my rights.  
 
 
I, ………………………………………., AGREE to take part in the study “Correlating clinical disease state 
of the shoulder after treatment for breast cancer with biomarkers of inflammation and angiogenesis and their 
associated genetic variants” 
 
(initial  boxes where appropriate) 
I agree to give a blood sample for protein studies  
 
I agree to give a blood sample for genetic studies related to this study only      
 
I agree to my DNA being stored for a maximum period of 10years 
 
I authorise my doctor to provide relevant clinical details to the  
Department of Human Biology, UCT. 
 
 
Research Volunteer:  
 
Signature: ________________________  
 
Date:        ________________________  
 
Name:      ________________________  
                             Please Print  
 
Volunteer: Please sign both copies of this page  
 
Interviewer Obtaining Consent:  
 
Signature: ________________________  
 
Date:        ________________________  
    
Name:      ________________________  
                            Please Print  















How severe is your pain? 
 
Circle the number that best describes your pain where: 0 = no pain and 10 = the worst pain imaginable 
 
1.At its worst? 0 1 2 3 4 5 6 7 8 9 10 
2.When lying on the involved side? 0 1 2 3 4 5 6 7 8 9 10 
3.Reaching for something on a high shelf? 0 1 2 3 4 5 6 7 8 9 10 
4.Touching the back of your neck? 0 1 2 3 4 5 6 7 8 9 10 












How much difficulty do you have? 
 
Circle the number that best describes your experience where: 0 = no difficulty and 10 = so difficult it requires help 
 
1.Washing your hair? 0 1 2 3 4 5 6 7 8 9 10 
2.Washing your back? 0 1 2 3 4 5 6 7 8 9 10 
3.Putting on an undershirt or jumper? 0 1 2 3 4 5 6 7 8 9 10 
4.Putting on a shirt that buttons down the front? 0 1 2 3 4 5 6 7 8 9 10 
5.Putting on your pants? 0 1 2 3 4 5 6 7 8 9 10 
6.Placing an object on a high shelf? 0 1 2 3 4 5 6 7 8 9 10 
7.Carrying a heavy object of 10 pounds (4.5 kilograms) 0 1 2 3 4 5 6 7 8 9 10 








 Patient #:  
Assessment #:   
Date:  
Clinical staff to circle: 
Rating decision: 6 >5 = H  OR  5/8≥5 =H  OR   5/8 are 3-5 = I  OR  L 
Clinical staff to circle: 












Participant #:  Weight (kg):  
GSH file #:   Height (m):  
RT file #:  BMI (kg/m2):  







Stage: I II III IV 
Tumour type: Invasive ductal Tubulolobular Mucinous Comedo Lobular DCIS Tubular NOS 
Tumour size (mm):  
 Tumour 
Tumour: T1 T2 T3 T4 
 Lymph nodes: N1 N2 N3 
Metastasis: M0 M1 
If M1, to where:  
# Resected nodes:  
Type of nodes:  
Receptor status: ER: Positive Negative PR: Positive Negative 
 Surgery 
Surgery type:  
Tissues removed:  
Procedure date:  
 Radiotherapy Chemotherapy Hormonal therapy 
Dose intensity (Gy):    
# Fractions:    
Dose frequency:    
Total doses:    
Field of radiation:    
Start date:    
End date:    
 Physiotherapy 
Start date symptoms:  
Time since surgery:  
Time 1st treatment since 
surgery: 
 
Total treatments:  
Time to resolution:  
Symptom recurrence:  























Supplementary statistical tables and R code 
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ssrs472 Summary 
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rs058 Summary 
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rs469 Summary 
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rs1516 Summary 
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rs4880 Summary 
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rs25487 Summary 
 
